<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12197412</article-id><article-id pub-id-type="pmcid-ver">PMC12197412.1</article-id><article-id pub-id-type="pmcaid">12197412</article-id><article-id pub-id-type="pmcaiid">12197412</article-id><article-id pub-id-type="pmid">40573900</article-id><article-id pub-id-type="doi">10.3390/vaccines13060569</article-id><article-id pub-id-type="publisher-id">vaccines-13-00569</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Vaccine Development for Human Pneumoviruses</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-7029-1327</contrib-id><name name-style="western"><surname>Mboup</surname><given-names initials="EB">Elhadji Birane</given-names></name><xref rid="af1-vaccines-13-00569" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hamelin</surname><given-names initials="M&#xC8;">Marie-&#200;ve</given-names></name><xref rid="af1-vaccines-13-00569" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00569" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9777-2968</contrib-id><name name-style="western"><surname>Dubois</surname><given-names initials="J">Julia</given-names></name><xref rid="af2-vaccines-13-00569" ref-type="aff">2</xref><xref rid="af3-vaccines-13-00569" ref-type="aff">3</xref><xref rid="af4-vaccines-13-00569" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7559-9527</contrib-id><name name-style="western"><surname>Rosa-Calatrava</surname><given-names initials="M">Manuel</given-names></name><xref rid="af2-vaccines-13-00569" ref-type="aff">2</xref><xref rid="af3-vaccines-13-00569" ref-type="aff">3</xref><xref rid="af4-vaccines-13-00569" ref-type="aff">4</xref><xref rid="af5-vaccines-13-00569" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3027-4662</contrib-id><name name-style="western"><surname>Boivin</surname><given-names initials="G">Guy</given-names></name><xref rid="af1-vaccines-13-00569" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00569" ref-type="aff">2</xref><xref rid="af5-vaccines-13-00569" ref-type="aff">5</xref><xref rid="c1-vaccines-13-00569" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Georgopoulos</surname><given-names initials="AP">Apostolos P.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00569"><label>1</label>Infectious and Immune Diseases Research Program, CHU de Qu&#233;bec-Universit&#233; Laval Research Center, Qu&#233;bec, QC G1V 4G2, Canada; <email>elhadji-birane.mboup@crchudequebec.ulaval.ca</email> (E.B.M.); <email>marie-eve.hamelin@crchudequebec.ulaval.ca</email> (M.-&#200;.H.); </aff><aff id="af2-vaccines-13-00569"><label>2</label>International Research Laboratory RESPIVIR France-Canada, Centre de Recherche en Infectiologie, Facult&#233; de M&#233;decine RTH Laennec, 69008 Lyon, France, Universit&#233; Claude Bernard Lyon 1, Lyon, France, CHU de Qu&#233;bec-Universit&#233; Laval Research Center, Qu&#233;bec, QC G1V 4G2, Canada; <email>julia.dubois@univ-lyon1.fr</email></aff><aff id="af3-vaccines-13-00569"><label>3</label>CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Universit&#233; Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France</aff><aff id="af4-vaccines-13-00569"><label>4</label>Virnext, Facult&#233; de M&#233;decine RTH Laennec, Universit&#233; Claude Bernard Lyon 1, Universit&#233; de Lyon, 69008 Lyon, France</aff><aff id="af5-vaccines-13-00569"><label>5</label>Department of Pediatrics, Faculty of Medicine, Universit&#233; Laval, Qu&#233;bec, QC G1V 0A6, Canada</aff><author-notes><corresp id="c1-vaccines-13-00569"><label>*</label>Correspondence: <email>guy.boivin@crchudequebec.ulaval.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>13</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">491455</issue-id><elocation-id>569</elocation-id><history><date date-type="received"><day>09</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-29 12:25:33.330"><day>29</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-13-00569.pdf"/><abstract><p>Background: Pneumoviruses are etiologic agents of respiratory tract infections and a major cause of morbidity and mortality worldwide, particularly affecting young children, the elderly, and individuals with underlying clinical conditions. These viruses are associated with a significant burden, particularly in low- and middle-income countries, where reported deaths attributable to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in young children are important. Recent developments have been noted in the prevention of pneumoviral infections. Method: In this review, we analyzed clinical trials of the approved RSV vaccines, as well as the recent prominent platform technologies used in RSV vaccine research. In addition, we discussed combination vaccines targeting RSV, HMPV, and Human Parainfluenza Virus Type 3 (HPIV3) that have entered clinical trials. Results: Recent advancements include the approval of three RSV vaccine candidates: AREXVY<sup>&#174;</sup>(GSK), ABRYSVO<sup>&#174;</sup>(Pfizer), and mRESVIA<sup>&#174;</sup>(Moderna). These vaccines are primarily intended for older adults, with ABRYSVO<sup>&#174;</sup> also capable of providing passive immunization to infants via maternal administration. The review highlights RSV vaccine platform technologies and combination vaccines currently being evaluated in clinical settings. Conclusions: While significant progress has been made in RSV vaccine development, especially with three approved candidates, the development of vaccines for HMPV remains an unmet medical need. Ongoing research in combination vaccines holds promise for broader protection against multiple respiratory viruses in the future.</p></abstract><kwd-group><kwd>pneumovirus</kwd><kwd>respiratory syncytial virus (RSV)</kwd><kwd>human metapneumovirus (HMPV)</kwd><kwd>lower respiratory tract infection (LRTI)</kwd><kwd>vaccine</kwd><kwd>clinical trial</kwd></kwd-group><funding-group><award-group><funding-source>Canadian Institutes of Health Research (CIHR)</funding-source><award-id>148361</award-id></award-group><funding-statement>This work was supported by Canadian Institutes of Health Research (CIHR): grant 148361. Gouvernement du Qu&#233;bec, Minist&#232;re de l&#8217;&#233;conomie, de l&#8217;innovation et de l&#8217;&#233;nergie (MEIE).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00569"><title>1. Introduction</title><p>Acute respiratory tract infections caused by viral pathogens have been recognized as a global public health threat and remain one of the leading causes of death [<xref rid="B1-vaccines-13-00569" ref-type="bibr">1</xref>]. According to the Global Burden of Disease (GBD) 2021 data, lower respiratory tract infections (LRTIs) have a death rate of 28.7 per 100,000, making them the seventh leading infectious cause of death worldwide in 2021. This ranking excluded COVID-19, which has radically impacted global mortality rates and was recognized as the second leading global cause of death [<xref rid="B2-vaccines-13-00569" ref-type="bibr">2</xref>]. LRTIs&#8212;affecting the bronchi, bronchioles, and alveoli&#8212;are a significant cause of mortality among infants and the elderly. Bronchiolitis in infants and pneumonia across all age groups are the primary contributors to LRTI-related mortality [<xref rid="B3-vaccines-13-00569" ref-type="bibr">3</xref>]. Human pneumoviruses, consisting of respiratory Syncytial Virus (RSV) and human metapneumovirus (HMPV), are key contributors to LRTI across a range of age groups and underlying diseases, with RSV being the most common cause of infections and hospitalizations in children under 2 years of age [<xref rid="B4-vaccines-13-00569" ref-type="bibr">4</xref>], with 3.3 million cases of LRTI and 101,400 deaths in children aged 0&#8211;60 months in 2019 [<xref rid="B5-vaccines-13-00569" ref-type="bibr">5</xref>]. Severe disease in older adults can worsen prior conditions and increase hospital admission and mortality rates [<xref rid="B6-vaccines-13-00569" ref-type="bibr">6</xref>]. Even though HMPV infections are typically less severe than those caused by RSV [<xref rid="B7-vaccines-13-00569" ref-type="bibr">7</xref>], their incidence is comparable to that of influenza and parainfluenza viruses. For instance, HMPV contributes to a significant number of hospitalizations each year, with an estimated 502,000 admissions among children under 5 in 2018 [<xref rid="B8-vaccines-13-00569" ref-type="bibr">8</xref>]. Outbreaks of RSV/HMPV in long-term care facilities are responsible for high mortality and morbidity rates in the elderly [<xref rid="B9-vaccines-13-00569" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-13-00569" ref-type="bibr">10</xref>]. Given the public health burden caused by RSV and HMPV, these two viruses are considered prime targets for the development of safe and effective vaccines. While there are currently no prophylactic modalities available for HMPV, monoclonal antibodies and market-approved vaccines targeting the viral fusion protein have been developed to prevent RSV infections. This review aims to cover recent developments in RSV vaccines, with an emphasis on the market-approved ones, as well as combined vaccines, including HMPV and/or Human Parainfluenza Virus Type 3 (HPIV3) in the clinical pipeline.</p></sec><sec id="sec2-vaccines-13-00569"><title>2. Pneumoviruses</title><p>Pneumoviruses are a family of enveloped, non-segmented, negative-sense, single-stranded, and linear RNA viruses in the order <italic toggle="yes">Mononegavirales</italic>. Formerly a subfamily within the <italic toggle="yes">Paramyxoviridae</italic> family, these viruses were reclassified in 2016 in the <italic toggle="yes">Pneumoviridae</italic> family with two genera, <italic toggle="yes">Orthopneumovirus</italic> (including RSV) and <italic toggle="yes">Metapneumovirus</italic> (including HMPV) [<xref rid="B11-vaccines-13-00569" ref-type="bibr">11</xref>]. RSV was first reported from chimpanzees in 1956, where it was initially referred to as the Chimpanzee Coryza Agent [<xref rid="B12-vaccines-13-00569" ref-type="bibr">12</xref>]. It was later identified in infants suffering from severe lower respiratory tract diseases (LRTD) [<xref rid="B13-vaccines-13-00569" ref-type="bibr">13</xref>]. The first identification of HMPV was reported in the Netherlands in 2001 [<xref rid="B14-vaccines-13-00569" ref-type="bibr">14</xref>], but the virus has been circulating unrecognized for decades due to its clinical manifestation being similar to that of other respiratory viruses and difficulties with its propagation in cell cultures [<xref rid="B15-vaccines-13-00569" ref-type="bibr">15</xref>].</p><sec id="sec2dot1-vaccines-13-00569"><title>2.1. Genome</title><p>RSV genomic RNA is approximately 15.2 kb in length, with 10 genes in the order 3&#8242;-NS1-NS2-N-P-M-SH-G-F-M2-L-5&#8242;, encoding for 11 proteins. In contrast, HMPV has a slightly smaller genome of around 13.2 kb, consisting of eight genes in the order 3&#8242;-N-P-M-F-M2-SH-G-L-5&#8242;, which encode for nine proteins [<xref rid="B16-vaccines-13-00569" ref-type="bibr">16</xref>]. While both orthopneumoviruses and metapneumoviruses encode similar sets of proteins, their genome organization differs, particularly in the arrangement of the envelope genes (attachment-G, fusion-F, and small hydrophobic-SH) (<xref rid="vaccines-13-00569-f001" ref-type="fig">Figure 1</xref>). Orthopneumoviruses contain two additional genes, NS1 and NS2, located upstream of the N gene, which encode proteins that suppress the synthesis and activity of host type 1 and type 3 interferon responses and also inhibit apoptosis [<xref rid="B17-vaccines-13-00569" ref-type="bibr">17</xref>]. Both viruses possess an M2 gene, which produces two proteins, M2-1 and M2-2, via overlapping open reading frames [<xref rid="B18-vaccines-13-00569" ref-type="bibr">18</xref>]. The genome is transcribed processively from the 3&#8242; end by the virion-associated polymerase complex. Gene expression exhibits a polar gradient, with decreasing levels of transcription as the distance from the 3&#8242; end increases. Transcription is guided by short (9&#8211;13 nt) conserved transcription start and termination/polyadenylation signals flanking each gene [<xref rid="B17-vaccines-13-00569" ref-type="bibr">17</xref>,<xref rid="B19-vaccines-13-00569" ref-type="bibr">19</xref>].</p></sec><sec id="sec2dot2-vaccines-13-00569"><title>2.2. Epidemiology</title><p>RSV and HMPV outbreaks exhibit seasonal patterns worldwide [<xref rid="B5-vaccines-13-00569" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-13-00569" ref-type="bibr">8</xref>]. In the northern hemisphere, RSV outbreaks generally occur from October or November to April or May of the following year, with peak activity in January or February. In the southern hemisphere, RSV infections typically peak during the winter months, from May to September, with the highest incidence often seen between May and July. The seasonal distribution of HMPV often mirrors that of RSV, although it can peak in late winter or early spring, depending on the region [<xref rid="B20-vaccines-13-00569" ref-type="bibr">20</xref>].</p><p>Each year, the two primary subtypes of RSV, RSV/A and RSV/B, along with various genotypes of each, either dominate or co-circulate during the RSV epidemic season [<xref rid="B21-vaccines-13-00569" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00569" ref-type="bibr">22</xref>], although infections with subtype A are potentially more frequently reported than those caused by subtype B [<xref rid="B23-vaccines-13-00569" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00569" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00569" ref-type="bibr">25</xref>]. A tendency for higher disease severity has been attributed to RSV/A; however, in more recent years, the severity between RSV/A and RSV/B subtypes has been similar [<xref rid="B22-vaccines-13-00569" ref-type="bibr">22</xref>].</p><p>A study by Cant&#250;-Flores et al. examined global and continental patterns of RSV circulation from the first report of human infection up to the end of 2020 and identified two primary RSV circulation patterns: continuous seasons dominated by RSV/A and alternating seasons in which both subtypes predominate [<xref rid="B26-vaccines-13-00569" ref-type="bibr">26</xref>]. These patterns were consistent across various regions, although the dominant RSV strain shifted globally from year to year. The most prevalent RSV/A genotype was NA1 (including ON1 strains), which accounted for 76.3% of cases, while the dominant RSV/B genotype was BA, making up 70.65%. Notably, a global predominance of these genotypes was observed around 2014 [<xref rid="B22-vaccines-13-00569" ref-type="bibr">22</xref>]. Although multiple RSV genotypes circulated simultaneously over time, the genetic diversity among these strains has declined since 2000 [<xref rid="B26-vaccines-13-00569" ref-type="bibr">26</xref>]. Resulting from nucleotide duplication in the G gene [<xref rid="B27-vaccines-13-00569" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00569" ref-type="bibr">28</xref>], ON1 and BA9 have notably emerged as the predominant lineages for RSV/A and RSV/B, respectively; however, the debate about whether these lineages should be classified as distinct new genotypes is still ongoing [<xref rid="B29-vaccines-13-00569" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00569" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-13-00569" ref-type="bibr">31</xref>].</p><p>HMPV is classified into two antigenically distinct groups: A and B [<xref rid="B32-vaccines-13-00569" ref-type="bibr">32</xref>]. Based on variations in the G and F genes, each group is further subdivided into two subgroups: A1, A2, B1, and B2 [<xref rid="B33-vaccines-13-00569" ref-type="bibr">33</xref>]. Phylogenetic analysis of the A2 subgroup based on the F gene has identified additional clades, including A2a, A2b, and A2c [<xref rid="B34-vaccines-13-00569" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00569" ref-type="bibr">35</xref>]. Notably, multiple subgroups of HMPV have often been found to co-circulate in the regions under investigation, whereas the precise relationship between disease severity and HMPV genotype remains unclear [<xref rid="B36-vaccines-13-00569" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00569" ref-type="bibr">37</xref>]. No consistent evidence supports the predominance of one subgroup over another, with several studies reporting the cocirculation of different subtypes or shifts in genotype prevalence across seasons; however, HMPV/A2 has been largely reported [<xref rid="B37-vaccines-13-00569" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00569" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00569" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00569" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00569" ref-type="bibr">41</xref>].</p><p>Implementation of non-pharmaceutical interventions (NPIs) due to COVID-19 led to changes regarding the epidemiology of respiratory viruses, such as a decrease in the circulation of RSV and HMPV during the pandemic [<xref rid="B42-vaccines-13-00569" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00569" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00569" ref-type="bibr">44</xref>]. Resurgence and off-season occurrence of RSV cases were observed after the relaxation of NPIs with more severe symptoms in na&#239;ve infants [<xref rid="B20-vaccines-13-00569" ref-type="bibr">20</xref>,<xref rid="B45-vaccines-13-00569" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00569" ref-type="bibr">46</xref>].</p><p>Both RSV and HMPV are etiologic agents of respiratory tract infections in people of all ages, but young children under 5 years of age, the elderly, and people with weakened immune systems are more likely to experience severe cases [<xref rid="B47-vaccines-13-00569" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00569" ref-type="bibr">48</xref>]. The primary risk factor for severe disease in childhood is young age, with infants in their first weeks of life being at the highest risk [<xref rid="B49-vaccines-13-00569" ref-type="bibr">49</xref>]. However, HMPV infections are less common and tend to occur in slightly older children compared to RSV [<xref rid="B50-vaccines-13-00569" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-13-00569" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-13-00569" ref-type="bibr">52</xref>]. Additional factors that increase the likelihood of severe illness include sex, household crowding, premature birth, and pre-existing lung conditions or congenital heart disease [<xref rid="B53-vaccines-13-00569" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-13-00569" ref-type="bibr">54</xref>]. Coinfections with both viruses are reported due to the overlapping of their seasonality, and reinfections are recurrent because of waning immunity throughout time [<xref rid="B20-vaccines-13-00569" ref-type="bibr">20</xref>,<xref rid="B41-vaccines-13-00569" ref-type="bibr">41</xref>,<xref rid="B55-vaccines-13-00569" ref-type="bibr">55</xref>]. The risk of severe disease in adults is increased by the presence of underlying chronic pulmonary disease, circulatory conditions, functional disabilities, and higher viral loads. Both viruses are also a nosocomial threat to hospitalized young infants, elderly, immunocompromised, and vulnerable individuals, with fatal infections in some cases [<xref rid="B7-vaccines-13-00569" ref-type="bibr">7</xref>,<xref rid="B15-vaccines-13-00569" ref-type="bibr">15</xref>,<xref rid="B56-vaccines-13-00569" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-13-00569" ref-type="bibr">57</xref>].</p></sec><sec id="sec2dot3-vaccines-13-00569"><title>2.3. Clinical Manifestations</title><p>RSV and HMPV are spread from person to person via respiratory droplets. The incubation period can vary from 3 to 5 days for HMPV [<xref rid="B58-vaccines-13-00569" ref-type="bibr">58</xref>] or 2 to 8 days for RSV, with a mean incubation of 4 to 6 days [<xref rid="B48-vaccines-13-00569" ref-type="bibr">48</xref>]. Typical symptoms include cough, rhinorrhea, sore throat, and fever, as well as lower respiratory tract manifestations such as wheezing, difficulty in breathing, and hypoxia [<xref rid="B47-vaccines-13-00569" ref-type="bibr">47</xref>,<xref rid="B50-vaccines-13-00569" ref-type="bibr">50</xref>]. Fever has been reported to be more frequent in young patients with HMPV infections [<xref rid="B51-vaccines-13-00569" ref-type="bibr">51</xref>]. Both viruses cause upper and lower respiratory tract infections, including bronchiolitis and pneumonia [<xref rid="B7-vaccines-13-00569" ref-type="bibr">7</xref>,<xref rid="B47-vaccines-13-00569" ref-type="bibr">47</xref>]. The onset of infection in infants and young children may cause severe bronchiolitis that can sometimes be fatal. Repeated upper respiratory tract infections are common in other age groups and range from subclinical infections to symptomatic upper respiratory tract diseases. In older adults aged 65 years and over, infections lead to an increase in hospitalization and mortality [<xref rid="B56-vaccines-13-00569" ref-type="bibr">56</xref>]. Asthma exacerbations and acute exacerbations of chronic obstructive pulmonary diseases (COPD) are also observed [<xref rid="B41-vaccines-13-00569" ref-type="bibr">41</xref>,<xref rid="B59-vaccines-13-00569" ref-type="bibr">59</xref>].</p></sec><sec id="sec2dot4-vaccines-13-00569"><title>2.4. Disease Burden</title><p>LRTIs are a leading cause of death and disability, particularly in children younger than 5 years old [<xref rid="B5-vaccines-13-00569" ref-type="bibr">5</xref>]. Around 15&#8211;50% of initial RSV infections in infants and young children affect the lower respiratory tract [<xref rid="B60-vaccines-13-00569" ref-type="bibr">60</xref>]. On a global scale estimate, RSV infections affected 24.8 million individuals in 2016, leading to approximately 76,000 deaths [<xref rid="B61-vaccines-13-00569" ref-type="bibr">61</xref>]. In 2019, it caused about 3.3 million cases of LRTI and 101,400 deaths in children under 60 months of age, while in infants aged 0&#8211;6 months, there were 6.6 million RSV-LRTI and 45,700 deaths [<xref rid="B5-vaccines-13-00569" ref-type="bibr">5</xref>]. Low- and middle-income countries are more heavily affected, accounting for over 95% of RSV-LRTI and over 97% of deaths across all age groups [<xref rid="B5-vaccines-13-00569" ref-type="bibr">5</xref>]. In the European Union, an average of 158,229 (95%CI, 140,865&#8211;175,592) RSV-associated hospitalizations are estimated among adults on an annual basis, with 92% of these hospitalizations occurring in adults &#8805; 65 years [<xref rid="B62-vaccines-13-00569" ref-type="bibr">62</xref>]. In the US, the annual attack rate for older adults generally ranges between 3 and 10%, resulting in an estimate of over 177,000 hospitalizations and 14,000 deaths [<xref rid="B63-vaccines-13-00569" ref-type="bibr">63</xref>]. In children &lt; 5 years, an average annual RSV-associated hospitalization rate of 4.0 per 1000 has been reported, with an even higher value among children 0&#8211;2 months old (23.8 per 1000) [<xref rid="B64-vaccines-13-00569" ref-type="bibr">64</xref>].</p><p>The annual cost of RSV-LRTI among the 3.7 million US infants &lt; 12 months, totaling 592,700, is estimated at USD 1.6 billion [<xref rid="B65-vaccines-13-00569" ref-type="bibr">65</xref>]. A study by Zhang et al. in 2020 reported that the estimated global cost of managing RSV-LRTI in young children was around &#8364;4.82 billion, making RSV-related diseases a significant economic burden on healthcare systems, governments, and society [<xref rid="B66-vaccines-13-00569" ref-type="bibr">66</xref>]. Nonetheless, according to Global Burden Disease 2021 data, there was a notable decrease of 63.2% in global RSV cases, which went down to 4.59 million, along with a 66.7% decrease in RSV deaths [<xref rid="B5-vaccines-13-00569" ref-type="bibr">5</xref>]. These declines are attributable to the implementation of non-pharmaceutical interventions during the COVID-19 pandemic, which limited the transmission of respiratory viruses [<xref rid="B67-vaccines-13-00569" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-13-00569" ref-type="bibr">68</xref>]. Moreover, the recent development of efficacious monoclonal antibodies and vaccines targeting the fusion protein to avert RSV infections could play a significant role in reducing RSV burden in the future, with substantial health and economic benefits [<xref rid="B69-vaccines-13-00569" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-13-00569" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-13-00569" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-13-00569" ref-type="bibr">72</xref>].</p><p>HMPV is predominantly observed in the pediatric population, particularly among older children, and seroprevalence studies indicate that nearly all are infected by the age of 5 [<xref rid="B73-vaccines-13-00569" ref-type="bibr">73</xref>]. This virus accounts for 6.1&#8211;6.4% of acute lower respiratory infections in patients younger than 20 years old [<xref rid="B74-vaccines-13-00569" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-13-00569" ref-type="bibr">75</xref>]. Although there is less global data assessing the burden of HMPV infections compared to RSV, several studies across the world have reported substantial HMPV rates in hospitalized adults and young children: India (5%) [<xref rid="B76-vaccines-13-00569" ref-type="bibr">76</xref>], China (4.08%) [<xref rid="B77-vaccines-13-00569" ref-type="bibr">77</xref>], Kenya (4.1%) [<xref rid="B78-vaccines-13-00569" ref-type="bibr">78</xref>], France (3%) [<xref rid="B79-vaccines-13-00569" ref-type="bibr">79</xref>], Japan (22.6%) [<xref rid="B80-vaccines-13-00569" ref-type="bibr">80</xref>], New Zealand (4.3%) [<xref rid="B81-vaccines-13-00569" ref-type="bibr">81</xref>]. A first 2018 global burden estimate of HMPV-related acute LRTI in young children revealed that 11.1 million cases were attributed to HMPV, resulting in 502,000 hospital admissions and 11,300 deaths worldwide. Notably, about 58% of the hospitalizations involved infants under 12 months of age, while 64% of the deaths that occurred in hospitals were among infants under 6 months. Furthermore, 79% of these deaths were reported in low- and middle-income countries [<xref rid="B8-vaccines-13-00569" ref-type="bibr">8</xref>].</p></sec></sec><sec id="sec3-vaccines-13-00569"><title>3. Fusion Protein</title><p>Viral glycoproteins anchored within viral envelopes contain specialized regions (peptides or loops), which are crucial for merging cell and viral membranes [<xref rid="B82-vaccines-13-00569" ref-type="bibr">82</xref>].</p><p>The fusion glycoproteins of pneumoviruses are part of the class I viral fusion protein family, processed through a cleavage step to generate an amino-terminal fusion peptide that mediates viral entry during infection [<xref rid="B83-vaccines-13-00569" ref-type="bibr">83</xref>]. The F protein is predominantly displayed on the viral surface alongside G glycoprotein and small hydrophobic (SH) protein, representing a primary target for immune response and, hence, for vaccine development [<xref rid="B84-vaccines-13-00569" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-13-00569" ref-type="bibr">85</xref>].</p><p>The F glycoproteins of RSV and HMPV exhibit structural similarities, sharing approximately 30% amino acid sequence (<xref rid="vaccines-13-00569-f001" ref-type="fig">Figure 1</xref>). To enable fusion, they transition from a biologically inactive precursor (F<sub>0</sub>) to a mature, cleaved, and metastable homotrimer (F<sub>1</sub>-F<sub>2</sub>). They possess the property to initiate membrane fusion without an additional attachment protein [<xref rid="B86-vaccines-13-00569" ref-type="bibr">86</xref>].</p><p>In contrast to many class I fusion proteins, the 574 amino acids RSV-F<sub>0</sub> undergoes cleavage at two polybasic sites (RARR109 and KKRKRR136) by furin-like proteases, yielding an internal peptide of 27 amino acids and two subunits F<sub>1</sub> and F<sub>2</sub> [<xref rid="B87-vaccines-13-00569" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-13-00569" ref-type="bibr">88</xref>]. Even though P27 is believed to be absent in the metastable prefusion F, it has been reported on the surface of infected cells, suggesting the possibility of a partial cleavage [<xref rid="B89-vaccines-13-00569" ref-type="bibr">89</xref>]. The functional metastable prefusion protein is obtained by the trimerization of an F<sub>1</sub>-F<sub>2</sub> disulfide bond-linked heterodimer [<xref rid="B90-vaccines-13-00569" ref-type="bibr">90</xref>]. Unlike RSV, HMPV F<sub>0</sub> lacking p27 is cleaved at a unique cleavage site by (serine) proteases such as TMPRSS2, generating F<sub>1</sub> and F<sub>2</sub> subunits which further trimerize into a functional prefusion HMPV-F [<xref rid="B91-vaccines-13-00569" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-13-00569" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-13-00569" ref-type="bibr">93</xref>]. The membrane-anchored, lollypop-shaped trimer consists of a membrane-proximal coiled-coil prefusion stalk and a single globular head domain [<xref rid="B94-vaccines-13-00569" ref-type="bibr">94</xref>].</p><p>During the membrane fusion process, the fusion peptide located at the N terminus of F<sub>2</sub> inserts into the cell membrane, bridging the two membranes. It occurs when a refolding leads to fusion, followed by the transition of F into a highly stable postfusion form [<xref rid="B90-vaccines-13-00569" ref-type="bibr">90</xref>,<xref rid="B92-vaccines-13-00569" ref-type="bibr">92</xref>,<xref rid="B95-vaccines-13-00569" ref-type="bibr">95</xref>]. In this final conformation, F trimers assume an overall cone shape [<xref rid="B96-vaccines-13-00569" ref-type="bibr">96</xref>].</p><p>The major antigenic sites of RSV-F described to date are &#216;, I, II, III, IV, and V. Site &#216;, located at the apex, is the target of the therapeutic monoclonal antibody (mAb) nirsevimab (Beyfortus<sup>&#174;</sup>, Sanofi, Paris, France) [<xref rid="B97-vaccines-13-00569" ref-type="bibr">97</xref>] and is specific to the prefusion conformation, along with the proximal site V [<xref rid="B84-vaccines-13-00569" ref-type="bibr">84</xref>]. Additionally, the most highly potent neutralizing antibodies (nAbs) elicited in response to natural infection (&gt;60%) are directed against these sites exposed in prefusion conformation, making them ideal targets for vaccine development [<xref rid="B98-vaccines-13-00569" ref-type="bibr">98</xref>]. Human mAbs binding site I are reported weakly neutralizing and are almost post-fusion specific [<xref rid="B99-vaccines-13-00569" ref-type="bibr">99</xref>]. Sites II, III, and IV are present in both conformations. Prophylactic mAb palivizumab (Synagis<sup>&#174;</sup>, AstraZeneca, Cambridge, UK) and the investigational clesrovimab (MK-1654, Merck, Darmstadt, Germany) bind to site II and site IV, respectively, and prevent fusion [<xref rid="B100-vaccines-13-00569" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-13-00569" ref-type="bibr">101</xref>]. Site III is highly conserved between RSV and HMPV and is targeted by the cross-neutralizing mAb MPE8 and the potent mAb RSV-199 [<xref rid="B102-vaccines-13-00569" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-13-00569" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-13-00569" ref-type="bibr">104</xref>]. Based on established nAbs, similar antigenic sites&#8212;&#216;, I, II, III, IV, V&#8212;have been identified for HMPV [<xref rid="B105-vaccines-13-00569" ref-type="bibr">105</xref>]. Sites I, II, III, and IV have prefusion and postfusion dual tropism [<xref rid="B106-vaccines-13-00569" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-13-00569" ref-type="bibr">107</xref>]. Similar to RSV-F, sites &#216; and V are prefusion-specific and represent potent neutralizing sites [<xref rid="B108-vaccines-13-00569" ref-type="bibr">108</xref>]. However, in contrast to RSV-F, the most frequent potent nAbs identified target epitopes in site IV, followed by sites III and II. In addition, there are HMPV nAbs targeting sites located in regions that span adjacent antigen sites (I and III, I and IV, II and III, II and V, and III and V), highlighting immunogenicity discrepancy of the F antigen between the two viruses [<xref rid="B109-vaccines-13-00569" ref-type="bibr">109</xref>]. Additionally, over 80% of nAbs against HMPV target F epitopes on both conformations[<xref rid="B109-vaccines-13-00569" ref-type="bibr">109</xref>]. However, the prefusion structure elicits higher neutralizing titers compared to the postfusion for certain genotypes [<xref rid="B110-vaccines-13-00569" ref-type="bibr">110</xref>].</p></sec><sec id="sec4-vaccines-13-00569"><title>4. RSV Vaccines</title><p>The prevention of RSV infection has been, until recently, an unmet medical need since its first recognition as a human pathogen. Immunization strategies focus on infants, children, pregnant women, and older adults because these groups are more vulnerable to this viral infection [<xref rid="B111-vaccines-13-00569" ref-type="bibr">111</xref>]. The aim of vaccination against RSV is primarily to prevent severe RSV-associated lower respiratory tract infection (RSV-LRTI) [<xref rid="B112-vaccines-13-00569" ref-type="bibr">112</xref>]. The initial failure to develop an effective vaccine based on inactivated virus has had a lasting impact on RSV vaccine development research [<xref rid="B113-vaccines-13-00569" ref-type="bibr">113</xref>]. However, significant progress has been made, and numerous innovative vaccine platforms have been developed since then for active immunization against RSV (<xref rid="vaccines-13-00569-t001" ref-type="table">Table 1</xref>). These include subunit vaccines, Live Attenuated Vaccines (LAV), vector-based vaccines, and mRNA vaccines [<xref rid="B114-vaccines-13-00569" ref-type="bibr">114</xref>].</p><sec id="sec4dot1-vaccines-13-00569"><title>4.1. Inactivated Vaccines</title><p>The journey of RSV vaccine development for use in humans began in the 1960s with a formalin-inactivated and alum-adjuvanted RSV vaccine (FI-RSV) grown in monkey kidney tissue culture. Upon vaccination, however, infants developed far more severe RSV infections than non-vaccinees, and this exaggerated response to natural infection has been termed enhanced respiratory disease (ERD) [<xref rid="B113-vaccines-13-00569" ref-type="bibr">113</xref>,<xref rid="B120-vaccines-13-00569" ref-type="bibr">120</xref>]. Serological analyses from patients who suffered from ERD showed that despite the development of anti-RSV binding antibodies, their neutralizing and fusion-inhibiting responses were weak [<xref rid="B121-vaccines-13-00569" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-13-00569" ref-type="bibr">122</xref>], possibly making these infants more vulnerable to severe RSV infections. Additionally, post-mortem lung tissue samples from the two lethal cases revealed immune complex deposition and complement activation, suggesting that the weak neutralizing antibodies could have heightened the risk of severe disease [<xref rid="B123-vaccines-13-00569" ref-type="bibr">123</xref>]. Additionally, marked Th2 cell activity (IL-4, IL-5, and IL-13)-related symptoms, pulmonary eosinophilia, and neutrophilic alveolitis were noted in various animal models [<xref rid="B124-vaccines-13-00569" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-13-00569" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-13-00569" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-13-00569" ref-type="bibr">127</xref>]. This pattern was similar to the lung histopathology observed in the infants who died following RSV infection, implying that an excessive reaction to the vaccine may also have played a role in the severe complications [<xref rid="B123-vaccines-13-00569" ref-type="bibr">123</xref>]. This early disappointment, along with concerns about the potential occurrence of FI-RSV-related ERD, hindered vaccine development.</p><p>Decades later, a purified &#946;-propiolactone inactivated RSV vaccine (BPL-RSV) adjuvanted with CpG ODN (TLR-9 ligand) and L18-MDP (NOD2 receptor ligand) was developed and evaluated in Balb/c mice. The results indicated that BPL-RSV activated APCs effectively in vitro and elicited local IgA, along with enhanced Th1-type IgG2a responses in vivo following mucosal immunization. TLR9/NOD2 ligands&#8217; addition facilitated the affinity maturation of RSV-specific IgG antibodies and shifted T-cell responses toward increased IFN-&#947; production, thus suggesting a Th1-dominated response. This immunization approach provided better protection against viral challenges without ERD occurrence, as evidenced by the lack of eosinophil infiltration in the lungs. It also suggests a potential administration approach for inactivated vaccines without priming ERD [<xref rid="B128-vaccines-13-00569" ref-type="bibr">128</xref>], which needs to be assessed more closely.</p></sec><sec id="sec4dot2-vaccines-13-00569"><title>4.2. Subunit Vaccines</title><p>In the aftermath of the failure of the FI-RSV vaccine to provide protection against infection, attention shifted to understanding the immune response to RSV. This ultimately led to the discovery of the fusion protein [<xref rid="B129-vaccines-13-00569" ref-type="bibr">129</xref>]. Antibodies directed against this protein were found to confer protection from RSV infection through passive immunization in animal models [<xref rid="B130-vaccines-13-00569" ref-type="bibr">130</xref>]. In the 1990s, the potential for passive protection against severe RSV disease by administration of immunoglobulins directed against F antigen led to the successful development of the humanized monoclonal antibodies palivizumab (Synagis<sup>&#174;</sup>, AstraZeneca) [<xref rid="B101-vaccines-13-00569" ref-type="bibr">101</xref>,<xref rid="B131-vaccines-13-00569" ref-type="bibr">131</xref>] for RSV prevention in high-risk infants [<xref rid="B132-vaccines-13-00569" ref-type="bibr">132</xref>] then nirsevimab in July 2023 (Beyfortus <sup>&#174;</sup>, Sanofi) [<xref rid="B97-vaccines-13-00569" ref-type="bibr">97</xref>,<xref rid="B133-vaccines-13-00569" ref-type="bibr">133</xref>]. The ability of genetically engineered chimeric FG glycoprotein subunit vaccine to circumvent ERD was demonstrated in the primate model [<xref rid="B125-vaccines-13-00569" ref-type="bibr">125</xref>], suggesting their potential use as a safer alternative to FI-RSV. Although these vaccines were revealed to be immunogenic and well tolerated in humans, they lack protective efficacy against severe disease in vulnerable groups [<xref rid="B134-vaccines-13-00569" ref-type="bibr">134</xref>,<xref rid="B135-vaccines-13-00569" ref-type="bibr">135</xref>,<xref rid="B136-vaccines-13-00569" ref-type="bibr">136</xref>,<xref rid="B137-vaccines-13-00569" ref-type="bibr">137</xref>,<xref rid="B138-vaccines-13-00569" ref-type="bibr">138</xref>]. More recently, research on active immunization has experienced a resurgence of interest with the discovery of the stabilization of the metastable conformation of the F fusion protein by McLellan et al. [<xref rid="B139-vaccines-13-00569" ref-type="bibr">139</xref>]. Their structure-based design of a stabilized RSV-F protein exposing site &#216; was a game changer and facilitated the improvement of a robust RSV immune response. This breakthrough prompted the development of several subunit RSV vaccines targeting the prefusion state, ultimately resulting in two vaccines currently approved to prevent RSV-LRTI (<xref rid="vaccines-13-00569-t001" ref-type="table">Table 1</xref>) [<xref rid="B140-vaccines-13-00569" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-13-00569" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-13-00569" ref-type="bibr">142</xref>,<xref rid="B143-vaccines-13-00569" ref-type="bibr">143</xref>].</p><sec id="sec4dot2dot1-vaccines-13-00569"><title>4.2.1. AREXVY<sup>&#174;</sup>-RSVPreF3 OA (GSK3844766A)</title><p>On 3 May 2023, the US Food and Drug Administration (FDA) approved the world&#8217;s first RSV vaccine for individuals aged 60 years and older and subsequently for people aged 50&#8211;59 years who are at increased risk of RSV-LRTD [<xref rid="B140-vaccines-13-00569" ref-type="bibr">140</xref>,<xref rid="B141-vaccines-13-00569" ref-type="bibr">141</xref>,<xref rid="B144-vaccines-13-00569" ref-type="bibr">144</xref>]. AREXVY<sup>&#174;</sup> is an intramuscularly delivered, single-dose subunit vaccine developed by GSK, created through stabilization of the RSV/A2-F protein in its trimeric prefusion form (RSVPreF3) combined with Adjuvant System 01 (AS01<sub>E</sub>) as an immunostimulant [<xref rid="B145-vaccines-13-00569" ref-type="bibr">145</xref>]. A phase 1/2 study involving young and older adults demonstrated strong potency and an excellent safety profile for the AS01<sub>E</sub> adjuvant combined with the highest dose of RSVPreF3 (120 &#956;g), which emerged as the preferred formulation (RSVPreF3 OA) for further studies [<xref rid="B146-vaccines-13-00569" ref-type="bibr">146</xref>]. In a phase 3 clinical trial, an unadjuvanted formulation of the vaccine was administered to pregnant women to prevent infections in their newborns up to six months. However, the GRACE trial was put on hold in February 2022 following the emergence of safety concerns regarding higher preterm births in vaccinees than in the placebo group [<xref rid="B147-vaccines-13-00569" ref-type="bibr">147</xref>]. The late evaluation phases of the RSVPreF3 OA vaccine in older adults demonstrated an acceptable safety profile (except one report of Guillain&#8211;Barr&#233; syndrome in an ongoing study [<xref rid="B148-vaccines-13-00569" ref-type="bibr">148</xref>]) with high efficacy against RSV-LRTD (82.6%), severe RSV-LRTD (94.1%), and RSV-associated acute respiratory infection (RSV-ARI) (71.7%) over one RSV season, regardless of RSV subtypes and pre-existing conditions [<xref rid="B115-vaccines-13-00569" ref-type="bibr">115</xref>]. Furthermore, this vaccine provided effective protection in older adults over two seasons with one dose, presenting an efficacy of 67.2% against RSV-LRTD and 78.8% against severe RSV-LRTD. Nonetheless, a second dose of vaccine did not seem to improve efficacy [<xref rid="B116-vaccines-13-00569" ref-type="bibr">116</xref>]. The coadministration of RSVPreF3 OA with quadrivalent seasonal influenza vaccines (FLU-QIV, FLU-QIV-HD, and FLU-aQIV) demonstrated an acceptable safety profile in older adults, with no clinically significant interference observed in the immune responses to either vaccine. Additionally, the immune response was not inferior when comparing sequential administration [<xref rid="B149-vaccines-13-00569" ref-type="bibr">149</xref>,<xref rid="B150-vaccines-13-00569" ref-type="bibr">150</xref>,<xref rid="B151-vaccines-13-00569" ref-type="bibr">151</xref>]. Studies assessing its coadministration with a COVID-19 mRNA vaccine (Omicron XBB.1.5), a pneumococcal vaccine (PCV20), and a herpes zoster subunit vaccine (HZ/su) are ongoing. An observational study among Medicare beneficiaries &#8805; 65 years, conducted between May 2023 and July 2024, suggests an increased risk of Guillain&#8211;Barr&#233; syndrome 42 days following vaccination with AREXVY<sup>&#174;</sup>. However, the observation is considered insufficient to establish a causal relationship [<xref rid="B144-vaccines-13-00569" ref-type="bibr">144</xref>].</p></sec><sec id="sec4dot2dot2-vaccines-13-00569"><title>4.2.2. ABRYSVO<sup>&#174;</sup>-RSVPreF</title><p>ABRYSVO<sup>&#174;</sup>, approved in May 2023, is a bivalent prefusion F vaccine (RSVpreF) developed by Pfizer. This intramuscularly administered single-dose vaccine contains 60 &#956;g of trimeric F glycoproteins from both major RSV subgroups (A and B) engineered for stability in the prefusion conformation. It is indicated for active immunization of pregnant women at 32&#8211;36 weeks of gestational age for the prevention of RSV-LRTD and severe LRTD in infants from birth through 6 months of age, and also for active immunization of individuals 60 years of age and older and individuals from 18 to 59 years who are at increased risk of RSV-LRTD [<xref rid="B152-vaccines-13-00569" ref-type="bibr">152</xref>]. Phase 1/2 studies showed good safety, tolerability, and immunogenicity with no benefit of adding either Al(OH)3 [<xref rid="B153-vaccines-13-00569" ref-type="bibr">153</xref>] or CpG/Al(OH)3 [<xref rid="B154-vaccines-13-00569" ref-type="bibr">154</xref>] as adjuvants in adults and healthy older adults, respectively. Phase 2 evaluations revealed an efficacy of 86.7% in preventing symptomatic RSV infections in adults in a challenge study [<xref rid="B155-vaccines-13-00569" ref-type="bibr">155</xref>] and efficient transplacental antibody transfer with immunization in the late second or third trimester of pregnancy [<xref rid="B156-vaccines-13-00569" ref-type="bibr">156</xref>]. The phase 3 MATISSE clinical trial assessed the efficacy and safety of RSVpreF in preventing RSV-associated lower respiratory tract illness in infants through maternal immunization between 24 and 36 months of gestation. Vaccine efficacy against medically attended severe LRTI within 90 days and 180 days after birth were 81.8% and 69.4%, respectively, with no safety concerns reported. Success criteria regarding protection against medically attended RSV-associated LRTI was not met with an efficacy of 57.1% within 90 days after birth [<xref rid="B118-vaccines-13-00569" ref-type="bibr">118</xref>]. The RENOIR study evaluated vaccine efficacy in older adults. It prevented RSV-associated lower respiratory tract illness with efficacies of 66.7% and 85.7%, defined by presenting at least two signs or symptoms and three signs or symptoms, respectively. Protection regarding RSV-associated acute respiratory illness was 62.1% without any evident safety issues [<xref rid="B117-vaccines-13-00569" ref-type="bibr">117</xref>]. The administration of ABRYSVO<sup>&#174;</sup> with tetanus, diphtheria, and pertussis vaccine (Tdap) and seasonal inactivated influenza vaccine (SIIV) were evaluated. Coadministration of RSVpreF with both vaccines was found to be safe, and non-inferiority was demonstrated. However, SIIV response was lower, and an inferior immune response was only seen for acellular pertussis antigen in the case of Tdap [<xref rid="B157-vaccines-13-00569" ref-type="bibr">157</xref>,<xref rid="B158-vaccines-13-00569" ref-type="bibr">158</xref>]. The MONET study assessing the vaccine in adults at increased risk of severe RSV disease has been recently completed [<xref rid="B159-vaccines-13-00569" ref-type="bibr">159</xref>]. Furthermore, the MORISSOT study, evaluating vaccine effectiveness in pregnant participants with HIV and their infants, along with a study assessing its coadministration with nirsevimab has been launched [<xref rid="B160-vaccines-13-00569" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-13-00569" ref-type="bibr">161</xref>]. Regarding AREXVY<sup>&#174;</sup>, the observational study suggests an increased risk of Guillain&#8211;Barr&#233; syndrome during the 42 days following vaccination with ABRYSVO<sup>&#174;</sup>, but the correlation is considered insufficient [<xref rid="B152-vaccines-13-00569" ref-type="bibr">152</xref>].</p></sec></sec><sec id="sec4dot3-vaccines-13-00569"><title>4.3. Live Attenuated Vaccines</title><p>Live Attenuated RSV vaccines are expected to provide numerous advantages for immunizing infants and young children. These vaccines do not prime enhanced RSV disease and effectively stimulate both systemic and local immune responses, including innate, humoral, and cellular immunity. Additionally, they can be administered intranasally and have the ability to replicate in the upper respiratory tract of young infants, even in the presence of maternal antibodies [<xref rid="B162-vaccines-13-00569" ref-type="bibr">162</xref>]. Since the initial efforts to generate LAVs for RSV through repeated passages or chemical mutagenesis [<xref rid="B163-vaccines-13-00569" ref-type="bibr">163</xref>,<xref rid="B164-vaccines-13-00569" ref-type="bibr">164</xref>,<xref rid="B165-vaccines-13-00569" ref-type="bibr">165</xref>,<xref rid="B166-vaccines-13-00569" ref-type="bibr">166</xref>], significant progress has been made using reverse genetics [<xref rid="B167-vaccines-13-00569" ref-type="bibr">167</xref>]. This technology has enabled the rational design of LAVs by deleting or modifying specific genes, resulting in a balanced profile of attenuation and immunogenicity. Notably, preclinical studies including Non-Human Primate reported that the &#916;M2-2 deletion inactivates viral replication and increases transcription, while the &#916;NS2 deletion optimizes the induction of innate immunity, along with G and SH deletions [<xref rid="B168-vaccines-13-00569" ref-type="bibr">168</xref>,<xref rid="B169-vaccines-13-00569" ref-type="bibr">169</xref>,<xref rid="B170-vaccines-13-00569" ref-type="bibr">170</xref>]. Several candidates have been developed, and pooled data from seven phase 1 clinical trials indicate an estimated efficacy of 67% and 88% against medically attended acute RSV illness and medically attended LRTI, respectively [<xref rid="B171-vaccines-13-00569" ref-type="bibr">171</xref>].</p><p>A promising candidate, RSV/&#916;NS2/&#916;1313/I1314L, sponsored by NIAID, is undergoing phase 3 clinical trial. The RSV/&#916;NS2/&#916;1313/I1314L is generated by combining deletion of the NS2 gene and the 1313 codon in the L gene, with a stabilizing attenuation phenotype at codon 1314 by substitution of leucine with isoleucine in the RSV/A2 genome. The vaccine, administered intranasally, showed good attenuation and immunogenicity profile in clinical trials involving 6&#8211;24 month-old infants and children [<xref rid="B172-vaccines-13-00569" ref-type="bibr">172</xref>,<xref rid="B173-vaccines-13-00569" ref-type="bibr">173</xref>]. It has been shown that incorporating the four amino acid changes (I79M, K191R, T357K, N371Y) derived from the RSV strain &#8220;line 19&#8221; into the F protein of this candidate improved its stability and production scalability [<xref rid="B174-vaccines-13-00569" ref-type="bibr">174</xref>].</p></sec><sec id="sec4dot4-vaccines-13-00569"><title>4.4. Recombinant Vector-Based Vaccines</title><p>Progress in recombinant virology has facilitated the design of vectored vaccines, including replicating and non-replicating viruses [<xref rid="B175-vaccines-13-00569" ref-type="bibr">175</xref>]. Adenoviruses and vaccinia virus vectors have been widely used in the development of recombinant RSV vaccines.</p><p>MVA-BN-RSV is an intramuscularly delivered candidate developed by Bavarian Nordic, based on the MVA (Modified Vaccinia Ankara)-BN backbone encoding the RSV F and G proteins and internal RSV N and M2 proteins [<xref rid="B176-vaccines-13-00569" ref-type="bibr">176</xref>]. This replication-defective vector effectively triggers viral protein expression without resulting in virion formation [<xref rid="B177-vaccines-13-00569" ref-type="bibr">177</xref>,<xref rid="B178-vaccines-13-00569" ref-type="bibr">178</xref>]. Phase 1 and phase 2 trials showed that MVA-BN-RSV elicits T-cells and antibody responses that persisted for 6 months and could be boosted at 12 months [<xref rid="B179-vaccines-13-00569" ref-type="bibr">179</xref>,<xref rid="B180-vaccines-13-00569" ref-type="bibr">180</xref>]. In a phase 3 study, vaccine efficacy was 42.9% against RSV-LRTD with &#8805;3 symptoms, 59.0% against LRTD with &#8805;2 symptoms, and 48.8% against ARD [<xref rid="B181-vaccines-13-00569" ref-type="bibr">181</xref>]. However, the primary end-point was not met for LRTD with &#8805;3 symptoms, leading to the discontinuation of the vaccine&#8217;s development.</p><p>Ad26.RSV.preF is another non-replicating vector based on adenovirus 26 encoding preF antigen, stabilized using unique amino acid substitutions focused on the stabilization of helix &#945;4 in the disordered apex [<xref rid="B182-vaccines-13-00569" ref-type="bibr">182</xref>]. Intramuscularly administered Ad26.RSV.preF exhibited an acceptable safety profile in older adults, healthy adults, and toddlers and induced sustained humoral and cellular immune responses [<xref rid="B183-vaccines-13-00569" ref-type="bibr">183</xref>,<xref rid="B184-vaccines-13-00569" ref-type="bibr">184</xref>]. Its coadministration with the influenza vaccine for simultaneous seasonal vaccination revealed no interference in immune response [<xref rid="B185-vaccines-13-00569" ref-type="bibr">185</xref>]. A human challenge study revealed that immunization with Ad26.RSV.preF provides protection against RSV infection, indicating potential effectiveness against natural RSV infections [<xref rid="B186-vaccines-13-00569" ref-type="bibr">186</xref>]. The combination of the Ad26.RSV.preF vector with the stabilized RSVpreF protein as a vaccine (Ad26.RSV.preF&#8211;RSVpreF) yielded enhanced immunogenicity, with efficacy rates of 80%, 76.1%, and 78.7% against RSV-LRTD in adults &#8805;65 over the course of one, two, and three seasons, respectively [<xref rid="B187-vaccines-13-00569" ref-type="bibr">187</xref>,<xref rid="B188-vaccines-13-00569" ref-type="bibr">188</xref>]. Despite these promising results, Janssen decided to abandon the RSV adult vaccine program as part of its efforts to focus on other medical fields.</p><p>Developed by Blue Lake Biotechnology, BLB-201 is an intranasally delivered viral-vectored candidate based on a parainfluenza virus 5 (PIV5) encoding the full length of RSV-F antigen, designed to prevent infection in older adults and children under 2 years of age. The vaccine is undergoing phase 2 evaluation, and data from the phase 1 clinical trial exhibited satisfactory safety and immunogenicity profiles in RSV-seropositive adults with nasal RSV-specific IgA detected in 48% of participants [<xref rid="B189-vaccines-13-00569" ref-type="bibr">189</xref>].</p></sec><sec id="sec4dot5-vaccines-13-00569"><title>4.5. mRNA Vaccines</title><p>mRNA vaccines consist of synthetic mRNA molecules coding for an antigen, which subsequently elicits an immune response following its translation in the host [<xref rid="B190-vaccines-13-00569" ref-type="bibr">190</xref>]. The COVID-19 pandemic urged the rapid development of the mRNA-LNP platform, which consists of lipid nanoparticles encapsulating mRNA molecules, for widespread human use. Research is ongoing to explore its applications against other pathogens [<xref rid="B191-vaccines-13-00569" ref-type="bibr">191</xref>]. The LNP formulation used in the SARS-CoV-2 vaccine SpikeVax<sup>&#174;</sup>, which is known to induce and enhance antibody and T-cell responses, has been adapted for the development of an mRNA RSV vaccine that codes for the stabilized prefusion F protein of the virus [<xref rid="B114-vaccines-13-00569" ref-type="bibr">114</xref>]. mRNA-1345, namely mRESVIA<sup>&#174;</sup>, is a single dose and intramuscularly delivered vaccine developed by Moderna. It contains 50 &#956;g of pre-F mRNA and is designed to protect adults &#8805;60 years against RSV-LRTD [<xref rid="B192-vaccines-13-00569" ref-type="bibr">192</xref>]. Phase 1 evaluations showed that mRNA-1345 was well tolerated and immunogenic in young and older adults [<xref rid="B193-vaccines-13-00569" ref-type="bibr">193</xref>,<xref rid="B194-vaccines-13-00569" ref-type="bibr">194</xref>]. The Phase 2/3 ConquerRSV study evaluated the efficacy and safety of this vaccine in older adults &#8805;60 years (<xref rid="vaccines-13-00569-t001" ref-type="table">Table 1</xref>). They observed that the vaccine exhibited an efficacy of 83.7% in preventing RSV-LRTD, characterized by at least two symptoms, and 82.4% in cases with at least three symptoms. Additionally, it demonstrated a 68.4% efficacy against RSV-associated acute respiratory disease. The vaccine provided protection against both RSV subtypes (A and B) across different age groups and among individuals with pre-existing conditions [<xref rid="B119-vaccines-13-00569" ref-type="bibr">119</xref>]. These results led to the approval of the vaccine by the FDA in June 2024 in individuals 60 years of age and older [<xref rid="B192-vaccines-13-00569" ref-type="bibr">192</xref>].</p><p>Pediatric mRNA-based RSV vaccines have also been developed. A phase 1 study evaluated two dosing regimens (15 and 30 &#956;g) of a monovalent RSV vaccine (mRNA-1345) and a bivalent RSV/HMPV vaccine (mRNA-1365) in healthy children aged from 5 months up to 24 months. In July 2024, the FDA notified a study pause in this phase 1 evaluation due to a safety concern: a potential increase for severe RSV-LRTI was observed with more cases identified in the vaccine groups compared with the placebo group, suggesting vaccine-associated enhanced respiratory disease (VAERD) [<xref rid="B195-vaccines-13-00569" ref-type="bibr">195</xref>]. Five cases of clinically significantly severe/very severe RSV-LRTI were reported in infants who received a dose of 15 &#956;g of mRNA-1345 (2 cases) or 15 &#956;g of mRNA-1365 (3 cases), compared to just one case in the placebo group. Among the six cases, five required hospitalization, including one infant who required mechanical ventilation. Moreover, the immune responses to the vaccine in infants who received mRNA-1345 (30 &#956;g) and had previously been exposed to nirsevimab were decreased compared to those who had not, indicating a potential interaction. The FDA stated that the discrepancy in severe and very severe cases of RSV-LRTI among recipients aged 5 to under 8 months receiving 15 &#956;g of mRNA-1345 or mRNA-1365 and placebo raises concerns for future development of non-living RSV pediatric vaccines. The trial was put on hold after those concerns were observed [<xref rid="B195-vaccines-13-00569" ref-type="bibr">195</xref>].</p></sec></sec><sec id="sec5-vaccines-13-00569"><title>5. Combined Vaccines Including HMPV</title><p>Despite the fact that vaccine development for pneumoviruses has been primarily focused on RSV due to its greater burden compared to HMPV, significant efforts have been undertaken to develop vaccines for the latter since its discovery in 2001. The first HMPV vaccine tested in humans was a mucosal LAV in which the Phosphoprotein (P) gene was replaced by the one from its avian counterpart AMPV (rHMPV-Pa). In a phase 1 study, the rHMPV-Pa candidate successfully restricted viral replication in healthy adults and seropositive children but presented an over-attenuated profile in seronegative children as evidenced by illness occurrence in half of the vaccine recipients and HMPV-positive RT-PCR results, leading to its discontinuation [<xref rid="B196-vaccines-13-00569" ref-type="bibr">196</xref>]. At the time of this writing, no vaccine has been approved for HMPV. However, combined HMPV vaccine candidates that also target either RSV or HPIV3 or simultaneously both are currently under clinical trials (<xref rid="vaccines-13-00569-t002" ref-type="table">Table 2</xref>). </p><p>Two bivalent candidates based on the mRNA technology, mRNA-1653 and mRNA-1365, have been developed by Moderna. mRNA-1365 targets RSV and HMPV, and its evaluation as a pediatric vaccine has been discussed in the RSV mRNA vaccines section. In addition to the enhanced respiratory diseases related to RSV, cases of HMPV hospitalization following infection have been reported in two vaccinees [<xref rid="B195-vaccines-13-00569" ref-type="bibr">195</xref>]. The second candidate, mRNA-1653, has been developed for the prevention of respiratory diseases associated with HMPV and HPIV3 infections. It represents the first combination mRNA vaccine simultaneously targeting these two viruses and encodes two distinct nucleoside-modified mRNA: the full-length fusion proteins of HMPV and HPIV3 co-formulated in an LNP [<xref rid="B197-vaccines-13-00569" ref-type="bibr">197</xref>]. Phase 1 evaluations in healthy adults and children aged 18&#8211;55 months demonstrated an acceptable safety profile, along with an increase in nAb titers for both viruses after one dose following intramuscular administration [<xref rid="B197-vaccines-13-00569" ref-type="bibr">197</xref>,<xref rid="B198-vaccines-13-00569" ref-type="bibr">198</xref>].</p><p>Sanofi Pasteur has developed F proteins-based mRNA vaccine candidates targeting RSV, HMPV and HPIV3. Trials assessing bivalent RSV/HMPV and trivalent RSV/HMPV/HPIV3 vaccines have been launched in 2024 [<xref rid="B202-vaccines-13-00569" ref-type="bibr">202</xref>,<xref rid="B203-vaccines-13-00569" ref-type="bibr">203</xref>,<xref rid="B204-vaccines-13-00569" ref-type="bibr">204</xref>,<xref rid="B205-vaccines-13-00569" ref-type="bibr">205</xref>].</p><p>IVX-A12 is a potential bivalent candidate targeting RSV and HMPV based on a virus-like particle (VLP) platform developed by Icosavax, recently acquired by AstraZeneca [<xref rid="B199-vaccines-13-00569" ref-type="bibr">199</xref>]. It includes two intramuscularly administered VLPs: RSV pre-F antigen (IVX-121) and HMPV pre-F antigen (IVX-241). Results from the phase 1 trial revealed an increase in nAbs titers for both viruses, with no safety concerns reported. Positive outcomes were observed from the phase 2 study in older adults with robust immune responses to all RSV and HMPV subgroups. IVX-A12 is phase 3-ready and has been granted Fast Track Designation from the FDA [<xref rid="B199-vaccines-13-00569" ref-type="bibr">199</xref>].</p><p>VXB-241 is a Vicebio Australia&#8217;s bivalent subunit candidate aiming to prevent RSV and HMPV infections. The vaccine was developed using a molecular clamp technology, consisting of a highly stable trimerization domain that, when incorporated into viral fusion proteins, effectively constrains them in their native prefusion conformation [<xref rid="B206-vaccines-13-00569" ref-type="bibr">206</xref>]. This technology has been used for the preclinical development of vaccines against diverse pathogens, including influenza A, SARS-CoV-2, and HPIV3 [<xref rid="B207-vaccines-13-00569" ref-type="bibr">207</xref>,<xref rid="B208-vaccines-13-00569" ref-type="bibr">208</xref>,<xref rid="B209-vaccines-13-00569" ref-type="bibr">209</xref>]. A phase 1 trial for VXB-241 started in 2024, with recruitment still in progress [<xref rid="B200-vaccines-13-00569" ref-type="bibr">200</xref>,<xref rid="B209-vaccines-13-00569" ref-type="bibr">209</xref>].</p><p>B/HPIV3/HMPV-PreF-A and B/HPIV3/HMPV-F-B365 are LAVs Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) vectored vaccines expressing the fusion proteins of HMPV. These two LAVs, developed by NIAID, are intended to protect against HMPV and HPIV3, and recruitment for the phase 1 study is still ongoing [<xref rid="B201-vaccines-13-00569" ref-type="bibr">201</xref>].</p><p>Among candidates in preclinical development, a mucosal bivalent LAV against HMPV and RSV developed by Vaxxel holds promise for preventing pneumovirus-induced diseases. The candidate was developed using an HMPV_&#916;SH (Metavac<sup>&#174;</sup>) backbone, which has demonstrated efficacy in protecting mice against HMPV infection following intranasal immunization [<xref rid="B210-vaccines-13-00569" ref-type="bibr">210</xref>]. Using this platform, the F gene of RSV/A2 was inserted alongside the endogenous HMPV-F gene, yielding the bivalent candidate Metavac<sup>&#174;</sup>-RSV [<xref rid="B211-vaccines-13-00569" ref-type="bibr">211</xref>]. The latter efficiently expressed the exogenous RSV-F gene and replicated to high titers in vitro. Studies using the murine model demonstrated a good safety profile, strong immunogenicity, and protection against lethal challenges with RSV and HMPV [<xref rid="B211-vaccines-13-00569" ref-type="bibr">211</xref>]. Initiation of a phase 1 clinical trial should take place in 2026 [<xref rid="B212-vaccines-13-00569" ref-type="bibr">212</xref>].</p></sec><sec id="sec6-vaccines-13-00569"><title>6. Perspective</title><p>Pneumoviruses are related to significant morbidity and mortality, justifying the need for preventive modalities, including vaccines (see timeline in <xref rid="vaccines-13-00569-f002" ref-type="fig">Figure 2</xref>). The development of RSV vaccines has faced setbacks, especially with early inactivated vaccines, due to concern about vaccine-associated enhanced respiratory disease. The stabilization of the fusion protein in its prefusion form has marked a turning point in RSV vaccine research. It resulted in three vaccines now approved for use in older adults and pregnant women, demonstrating satisfying efficacy and safety results, with substantial economic and health benefits expected. However, it remains important to evaluate the long-term immunity provided by these vaccines over multiple seasons and the impact of revaccination, considering the seasonality of this virus. In addition, establishing standardized antibody thresholds would be essential to more accurately evaluate vaccine effectiveness and ensure consistent assessments.</p><p>The halt in Moderna&#8217;s pediatric mRNA vaccine study due to safety concerns related to VAERD highlights the complexity of vaccine development in this age group. Therefore, vaccine development should consider factors influencing immune response, such as age, pre-existing conditions, and prior exposure to the virus. Moreover, with a view to mitigating VAERD risk in seronegative children, preclinical studies should assess the four key immune properties recommended by WHO: (1) the ability to induce anti-RSV nAb, (2) the capacity to avoid generating non-nAbs and have a low binding IgG/nAb ratio, (3) the prevention of strong Th2-type CD4+ T cell response, and (4) ensuring the absence of alveolitis following a valid live RSV challenge. Coadministration studies with other vaccines have shown non-inferiority of immune responses, which is favorable for the successful rollout of vaccination programs.</p><p>Recently, there has been increasing interest in developing combination vaccines that target RSV, HMPV, and HPIV3 for a global reduction in the burden associated with these respiratory pathogens. These combination approaches are expected to offer broader protection and could eventually help mitigate a possible risk of HMPV and HPIV3 infections emerging as a result of RSV vaccination alone. Since the risk of VAERD is also associated with HMPV and HPIV3, it is crucial to establish specific parameters defining ERD related to these combinations, as well as identifying suitable vaccine immune properties that may help avoid this risk.</p></sec><sec sec-type="conclusions" id="sec7-vaccines-13-00569"><title>7. Conclusions</title><p>RSV and HMPV are recognized human pathogens responsible for life-threatening diseases with significant burdens in vulnerable groups, such as children and older adults. Efforts to implement prophylactic measures have led to the development of approved monoclonal antibodies and structure-based vaccines, which have proven their safety and efficacy in protecting against RSV-LRTI and severe LRTI. However, progress still needs to be made in the development of safe pediatric RSV vaccines, which could greatly reduce the impact of RSV-related diseases, particularly in low- and middle-income countries, where this virus remains a significant public health threat.</p><p>Moreover, greater emphasis should be placed on mucosal LAVs as they can elicit local immunity at mucosal sites while inducing robust and long-lasting systemic immune responses with reduced risk of priming ERD. Recent advances in combination vaccine design offer significant promise for the development of pan-pneumovirus vaccines that target both RSV and HMPV and, more broadly, pan-respiratory vaccines.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: G.B.; Writing&#8212;original draft preparation: E.B.M.; Writing&#8212;review and editing: M.-&#200;.H., G.B., J.D., M.R.-C. and E.B.M.; Supervision, project administration, and funding acquisition: G.B. All authors have read and agreed to the published version of the manuscript..</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>G.B., M.R.C., J.D., and M.-&#200;.H. are cofounders and shareholders of Vaxxel.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00569"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safiri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mahmoodpoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolahi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Nejadghaderi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sullman</surname><given-names>M.J.M.</given-names></name><name name-style="western"><surname>Mansournia</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ansarin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>M.</given-names></name></person-group><article-title>Global burden of lower respiratory infections during the last three decades</article-title><source>Front. Public Health</source><year>2023</year><volume>10</volume><elocation-id>1028525</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2022.1028525</pub-id><pub-id pub-id-type="pmid">36699876</pub-id><pub-id pub-id-type="pmcid">PMC9869262</pub-id></element-citation></ref><ref id="B2-vaccines-13-00569"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>IHME (Institute for Health Metrics and Evaluation)</collab></person-group><source>Global Burden of Disease 2021: Findings from the GBD 2021 Study</source><publisher-name>IHME</publisher-name><publisher-loc>Seattle, WA, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B3-vaccines-13-00569"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>H.</given-names></name></person-group><article-title>Trends in the global burden of lower respiratory infections: The knowns and the unknowns</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>1523</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00445-5</pub-id><pub-id pub-id-type="pmid">35964616</pub-id></element-citation></ref><ref id="B4-vaccines-13-00569"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Baggett</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Feikin</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hammitt</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Higdon</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Howie</surname><given-names>S.R.C.</given-names></name><name name-style="western"><surname>Deloria Knoll</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>O.S.</given-names></name><etal/></person-group><article-title>Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>757</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30721-4</pub-id><pub-id pub-id-type="pmid">31257127</pub-id><pub-id pub-id-type="pmcid">PMC6727070</pub-id></element-citation></ref><ref id="B5-vaccines-13-00569"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Blau</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Feikin</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>A Madhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Omer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.A.F.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>2047</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00478-0</pub-id><pub-id pub-id-type="pmid">35598608</pub-id><pub-id pub-id-type="pmcid">PMC7613574</pub-id></element-citation></ref><ref id="B6-vaccines-13-00569"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Sy</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Ackerson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Solano</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Slezak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>A Fischetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>V.</given-names></name></person-group><article-title>Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>1298</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa361</pub-id><pub-id pub-id-type="pmid">32591787</pub-id></element-citation></ref><ref id="B7-vaccines-13-00569"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Serres</surname><given-names>G.</given-names></name><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gilca</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abed</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rochette</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bergeron</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>D&#233;ry</surname><given-names>P.</given-names></name></person-group><article-title>Human Metapneumovirus Infections in Hospitalized Children</article-title><source>Emerging Infectious Diseases.</source><year>2003</year><volume>9</volume><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.3201/eid0906.030017</pub-id><pub-id pub-id-type="pmid">12781001</pub-id><pub-id pub-id-type="pmcid">PMC3000156</pub-id></element-citation></ref><ref id="B8-vaccines-13-00569"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deloria-Knoll</surname><given-names>M.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Basnet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bassat</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Chittaganpitch</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: A systematic review and modelling study</article-title><source>Lancet Glob. Health</source><year>2021</year><volume>9</volume><fpage>e33</fpage><lpage>e43</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(20)30393-4</pub-id><pub-id pub-id-type="pmid">33248481</pub-id><pub-id pub-id-type="pmcid">PMC7783516</pub-id></element-citation></ref><ref id="B9-vaccines-13-00569"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Appelgate</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pelz</surname><given-names>R.</given-names></name></person-group><article-title>An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility for the elderly in Oregon</article-title><source>J. Clin. Virol.</source><year>2012</year><volume>53</volume><fpage>171</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2011.10.010</pub-id><pub-id pub-id-type="pmid">22078146</pub-id></element-citation></ref><ref id="B10-vaccines-13-00569"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrante</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bancej</surname><given-names>C.</given-names></name><name name-style="western"><surname>Atchessi</surname><given-names>N.</given-names></name></person-group><article-title>Disease burden attributable to respiratory syncytial virus outbreaks in long-term care</article-title><source>Can. Commun. Dis. Rep.</source><year>2024</year><volume>50</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.14745/ccdr.v50i12a03</pub-id><pub-id pub-id-type="pmid">38655245</pub-id><pub-id pub-id-type="pmcid">PMC11037883</pub-id></element-citation></ref><ref id="B11-vaccines-13-00569"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afonso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Amarasinghe</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>B&#225;nyai</surname><given-names>K.</given-names></name><name name-style="western"><surname>B&#224;o</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Basler</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Bavari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bejerman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blasdell</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Briand</surname><given-names>F.-X.</given-names></name><name name-style="western"><surname>Briese</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Taxonomy of the order Mononegavirales: Update 2016</article-title><source>Arch. Virol.</source><year>2016</year><volume>161</volume><fpage>2351</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1007/s00705-016-2880-1</pub-id><pub-id pub-id-type="pmid">27216929</pub-id><pub-id pub-id-type="pmcid">PMC4947412</pub-id></element-citation></ref><ref id="B12-vaccines-13-00569"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blount</surname><given-names>R.</given-names></name><name name-style="western"><surname>Savage</surname><given-names>R.</given-names></name></person-group><article-title>An outbreak of severe pneumonia due to respiratory syncytial virus in isolated arctic population</article-title><source>Am. J. Epidemiol.</source><year>1957</year><volume>101</volume><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.aje.a112090</pub-id><pub-id pub-id-type="pmid">163574</pub-id></element-citation></ref><ref id="B13-vaccines-13-00569"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chanock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Finberg</surname><given-names>L.</given-names></name></person-group><article-title>Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children</article-title><source>Am. J. Hyg.</source><year>1957</year><volume>66</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">13478579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.aje.a119902</pub-id></element-citation></ref><ref id="B14-vaccines-13-00569"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Hoogen</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>A newly discovered human pneumovirus isolated from young children with respiratory tract disease</article-title><source>Nat. Med.</source><year>2001</year><volume>7</volume><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/89098</pub-id><pub-id pub-id-type="pmid">11385510</pub-id><pub-id pub-id-type="pmcid">PMC7095854</pub-id></element-citation></ref><ref id="B15-vaccines-13-00569"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafagati</surname><given-names>N.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name></person-group><article-title>Human metapneumovirus&#8212;What we know now</article-title><source>F1000Research</source><year>2018</year><volume>7</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.12688/f1000research.12625.1</pub-id><pub-id pub-id-type="pmid">29744035</pub-id><pub-id pub-id-type="pmcid">PMC5795268</pub-id></element-citation></ref><ref id="B16-vaccines-13-00569"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cifuentes-Mu&#241;oz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ellis Dutch</surname><given-names>R.</given-names></name></person-group><article-title>To assemble or not to assemble: The changing rules of pneumovirus transmission</article-title><source>Virus Res.</source><year>2019</year><volume>265</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2019.03.002</pub-id><pub-id pub-id-type="pmid">30844414</pub-id><pub-id pub-id-type="pmcid">PMC6461558</pub-id></element-citation></ref><ref id="B17-vaccines-13-00569"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rima</surname><given-names>B.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Easton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kurath</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maisner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rota</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>ICTV virus taxonomy profile: Pneumoviridae</article-title><source>J. Gen. Virol.</source><year>2017</year><volume>98</volume><fpage>2912</fpage><lpage>2913</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000959</pub-id><pub-id pub-id-type="pmid">29087278</pub-id><pub-id pub-id-type="pmcid">PMC5775899</pub-id></element-citation></ref><ref id="B18-vaccines-13-00569"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gould</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Easton</surname><given-names>A.J.</given-names></name></person-group><article-title>Coupled Translation of the Second Open Reading Frame of M2 mRNA Is Sequence Dependent and Differs Significantly within the Subfamily Pneumovirinae</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>8488</fpage><lpage>8496</lpage><pub-id pub-id-type="doi">10.1128/JVI.00457-07</pub-id><pub-id pub-id-type="pmid">17522208</pub-id><pub-id pub-id-type="pmcid">PMC1951343</pub-id></element-citation></ref><ref id="B19-vaccines-13-00569"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#233;spedes</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Palavecino</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kalergis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>S.M.</given-names></name></person-group><article-title>Modulation of host immunity by the human metapneumovirus</article-title><source>Clin. Microbiol. Rev.</source><year>2016</year><volume>29</volume><fpage>795</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1128/CMR.00081-15</pub-id><pub-id pub-id-type="pmid">27413096</pub-id><pub-id pub-id-type="pmcid">PMC5010756</pub-id></element-citation></ref><ref id="B20-vaccines-13-00569"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>B.</given-names></name></person-group><article-title>Changes in the epidemiological patterns of respiratory syncytial virus and human metapneumovirus infection among pediatric patients and their correlation with severe cases: A long-term retrospective study</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2024</year><volume>14</volume><elocation-id>1435294</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2024.1435294</pub-id><pub-id pub-id-type="pmid">39286815</pub-id><pub-id pub-id-type="pmcid">PMC11404324</pub-id></element-citation></ref><ref id="B21-vaccines-13-00569"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biagi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lanari</surname><given-names>M.</given-names></name></person-group><article-title>Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1717</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18081717</pub-id><pub-id pub-id-type="pmid">28783078</pub-id><pub-id pub-id-type="pmcid">PMC5578107</pub-id></element-citation></ref><ref id="B22-vaccines-13-00569"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuttens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moyersoen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Curcio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aponte-Torres</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Baay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vroling</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Begier</surname><given-names>E.</given-names></name></person-group><article-title>Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures</article-title><source>Infect. Dis. Ther.</source><year>2024</year><volume>13</volume><fpage>1725</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1007/s40121-024-01012-2</pub-id><pub-id pub-id-type="pmid">38971918</pub-id><pub-id pub-id-type="pmcid">PMC11266343</pub-id></element-citation></ref><ref id="B23-vaccines-13-00569"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVincenzo</surname><given-names>J.P.</given-names></name></person-group><article-title>Natural infection of infants with respiratory syncytial virus subgroups A and B: A study of frequency, disease severity, and viral load</article-title><source>Pediatr. Res.</source><year>2004</year><volume>56</volume><fpage>914</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1203/01.PDR.0000145255.86117.6A</pub-id><pub-id pub-id-type="pmid">15470202</pub-id></element-citation></ref><ref id="B24-vaccines-13-00569"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laham</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mansbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Espinola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>C.J.</given-names></name></person-group><article-title>Clinical Profiles of Respiratory Syncytial Virus Subtypes A AND B Among Children Hospitalized with Bronchiolitis</article-title><source>Pediatr. Infect. Dis. J.</source><year>2017</year><volume>36</volume><fpage>808</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001596</pub-id><pub-id pub-id-type="pmid">28383391</pub-id><pub-id pub-id-type="pmcid">PMC5556381</pub-id></element-citation></ref><ref id="B25-vaccines-13-00569"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciarlitto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vittucci</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Antilici</surname><given-names>L.</given-names></name><name name-style="western"><surname>Concato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Di Camillo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zangari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Villani</surname><given-names>A.</given-names></name></person-group><article-title>Respiratory Syncityal Virus A and B: Three bronchiolitis seasons in a third level hospital in Italy</article-title><source>Ital. J. Pediatr.</source><year>2019</year><volume>45</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1186/s13052-019-0704-0</pub-id><pub-id pub-id-type="pmid">31462274</pub-id><pub-id pub-id-type="pmcid">PMC6712785</pub-id></element-citation></ref><ref id="B26-vaccines-13-00569"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cant&#250;-Flores</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rivera-Alfaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Escalante</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Noyola</surname><given-names>D.E.</given-names></name></person-group><article-title>Global distribution of respiratory syncytial virus A and B infections: A systematic review</article-title><source>Pathog. Glob. Health</source><year>2022</year><volume>116</volume><fpage>398</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1080/20477724.2022.2038053</pub-id><pub-id pub-id-type="pmid">35156555</pub-id><pub-id pub-id-type="pmcid">PMC9518599</pub-id></element-citation></ref><ref id="B27-vaccines-13-00569"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eshaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duvvuri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nadarajah</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Low</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Gubbay</surname><given-names>J.B.</given-names></name></person-group><article-title>Genetic vari- ability of human respiratory syncytial virus A strains circulating in Ontario: A novel genotype with a 72 nucleotide G gene duplication</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e32807</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032807</pub-id><pub-id pub-id-type="pmid">22470426</pub-id><pub-id pub-id-type="pmcid">PMC3314658</pub-id></element-citation></ref><ref id="B28-vaccines-13-00569"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Calder&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garcia-Garcia</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perez-Bre&#241;a</surname><given-names>P.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>J.A.</given-names></name></person-group><article-title>Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>7500</fpage><lpage>7512</lpage><pub-id pub-id-type="doi">10.1128/JVI.00345-10</pub-id><pub-id pub-id-type="pmid">20504933</pub-id><pub-id pub-id-type="pmcid">PMC2897623</pub-id></element-citation></ref><ref id="B29-vaccines-13-00569"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-K.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.-P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.-C.</given-names></name><etal/></person-group><article-title>Gradual replacement of all previously circulating respiratory syncytial virus A strain with the novel ON1 genotype in Lanzhou from 2010 to 2017</article-title><source>Medicine</source><year>2019</year><volume>98</volume><fpage>e15542</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000015542</pub-id><pub-id pub-id-type="pmid">31083208</pub-id><pub-id pub-id-type="pmcid">PMC6531141</pub-id></element-citation></ref><ref id="B30-vaccines-13-00569"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>T.Y.</given-names></name></person-group><article-title>Delayed respiratory syncytial virus outbreak in 2020 in Taiwan was correlated with two novel RSV-A genotype ON1 variants</article-title><source>Influ. Other Respir. Viruses</source><year>2022</year><volume>16</volume><fpage>511</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1111/irv.12951</pub-id><pub-id pub-id-type="pmcid">PMC8983888</pub-id><pub-id pub-id-type="pmid">34913593</pub-id></element-citation></ref><ref id="B31-vaccines-13-00569"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name></person-group><article-title>Molecular epidemiology of respiratory syncytial virus for 28 consecutive seasons (1990&#8211;2018) and genetic variability of the duplication region in the G gene of genotypes ON1 and BA in South Korea</article-title><source>Arch. Virol.</source><year>2020</year><volume>165</volume><fpage>1069</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1007/s00705-020-04580-z</pub-id><pub-id pub-id-type="pmid">32144544</pub-id></element-citation></ref><ref id="B32-vaccines-13-00569"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Hoogen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Herfst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sprong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cane</surname><given-names>P.</given-names></name><name name-style="western"><surname>Forleo-Neto</surname><given-names>E.</given-names></name><name name-style="western"><surname>DeSwart</surname><given-names>R.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.</given-names></name></person-group><article-title>Antigenic and genetic variability of human metapneumoviruses</article-title><source>Emerg. Infect. Dis.</source><year>2004</year><volume>10</volume><fpage>658</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.3201/eid1004.030393</pub-id><pub-id pub-id-type="pmid">15200856</pub-id><pub-id pub-id-type="pmcid">PMC3323073</pub-id></element-citation></ref><ref id="B33-vaccines-13-00569"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sloots</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Freymuth</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shemer-Avni</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ludewick</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>&#201;.</given-names></name></person-group><article-title>Global Genetic Diversity of Human Metapneumovirus Fusion Gene</article-title><source>Emerg. Infect. Dis.</source><year>2004</year><volume>10</volume><fpage>1154</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.3201/eid1006.031097</pub-id><pub-id pub-id-type="pmid">15207075</pub-id><pub-id pub-id-type="pmcid">PMC3323143</pub-id></element-citation></ref><ref id="B34-vaccines-13-00569"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huck</surname><given-names>B.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>G.</given-names></name><name name-style="western"><surname>Neumann-Haefelin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Puppe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weigl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Falcone</surname><given-names>V.</given-names></name></person-group><article-title>Novel human metapneumovirus sublineage</article-title><source>Emerg. Infect. Dis.</source><year>2006</year><volume>12</volume><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.3201/eid1201.050772</pub-id><pub-id pub-id-type="pmid">16494734</pub-id><pub-id pub-id-type="pmcid">PMC3291390</pub-id></element-citation></ref><ref id="B35-vaccines-13-00569"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saikusa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sekizuka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Usuku</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name></person-group><article-title>Recent Molecular Evolution of Human Metapneumovirus (HMPV): Subdivision of HMPV A2b Strains</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1280</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8091280</pub-id><pub-id pub-id-type="pmid">32839394</pub-id><pub-id pub-id-type="pmcid">PMC7564156</pub-id></element-citation></ref><ref id="B36-vaccines-13-00569"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roussy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carbonneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ouakki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papenburg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamelin</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Serres</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Human metapneumovirus viral load is an important risk factor for disease severity in young children</article-title><source>J. Clin. Virol.</source><year>2014</year><volume>60</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.03.001</pub-id><pub-id pub-id-type="pmid">24686044</pub-id></element-citation></ref><ref id="B37-vaccines-13-00569"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otomaru</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.A.T.</given-names></name><name name-style="western"><surname>Vo</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Toizumi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Mizuta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moriuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>M.X.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>L.-M.</given-names></name></person-group><article-title>A decade of human metapneumovirus in hospitalized children with acute respiratory infection: Molecular epidemiology in central Vietnam, 2007&#8211;2017</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>15757</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-42692-z</pub-id><pub-id pub-id-type="pmid">37735242</pub-id><pub-id pub-id-type="pmcid">PMC10514255</pub-id></element-citation></ref><ref id="B38-vaccines-13-00569"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Kweon</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.K.</given-names></name></person-group><article-title>Clinical features, epidemiology, and climatic impact of genotype-specific human metapneumovirus infections: Long-term surveillance of hospitalized patients in south korea</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>70</volume><fpage>2683</fpage><lpage>2694</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz697</pub-id><pub-id pub-id-type="pmid">31353397</pub-id><pub-id pub-id-type="pmcid">PMC7108157</pub-id></element-citation></ref><ref id="B39-vaccines-13-00569"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Seasonal and Genetic Characteristics of Human Metapneumovirus Circulating&#8212;Henan Province, China, 2017&#8211;2023</article-title><source>China CDC Wkly.</source><year>2024</year><volume>6</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.46234/ccdcw2024.087</pub-id><pub-id pub-id-type="pmid">38846360</pub-id><pub-id pub-id-type="pmcid">PMC11150164</pub-id></element-citation></ref><ref id="B40-vaccines-13-00569"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Divarathna</surname><given-names>M.V.M.</given-names></name><name name-style="western"><surname>Rafeek</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Noordeen</surname><given-names>F.</given-names></name></person-group><article-title>A review on epidemiology and impact of human metapneumovirus infections in children using TIAB search strategy on PubMed and PubMed Central articles</article-title><source>Rev. Med. Virol.</source><year>2020</year><volume>30</volume><fpage>e2090</fpage><pub-id pub-id-type="doi">10.1002/rmv.2090</pub-id><pub-id pub-id-type="pmid">31788915</pub-id></element-citation></ref><ref id="B41-vaccines-13-00569"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frutos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuffini</surname><given-names>C.</given-names></name><name name-style="western"><surname>C&#225;mara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paglini</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>L.</given-names></name><name name-style="western"><surname>C&#225;mara</surname><given-names>A.</given-names></name></person-group><article-title>Human Metapneumovirus: Epidemiology and genotype diversity in children and adult patients with respiratory infection in C&#243;rdoba, Argentina</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0244093</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0244093</pub-id><pub-id pub-id-type="pmid">33370354</pub-id><pub-id pub-id-type="pmcid">PMC7769284</pub-id></element-citation></ref><ref id="B42-vaccines-13-00569"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agca</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akalin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saglik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hacimustafaoglu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Celebi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ener</surname><given-names>B.</given-names></name></person-group><article-title>Changing epidemiology of influenza and other respiratory viruses in the first year of COVID-19 pandemic</article-title><source>J. Infect. Public Health</source><year>2021</year><volume>14</volume><fpage>1186</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2021.08.004</pub-id><pub-id pub-id-type="pmid">34399190</pub-id></element-citation></ref><ref id="B43-vaccines-13-00569"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Winn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Budd</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Prill</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Steel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Midgley</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kniss</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Foust</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic&#8212;United States, 2020&#8211;2021</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2021</year><volume>70</volume><fpage>1013</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7029a1</pub-id><pub-id pub-id-type="pmid">34292924</pub-id><pub-id pub-id-type="pmcid">PMC8297694</pub-id></element-citation></ref><ref id="B44-vaccines-13-00569"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weissbrich</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Knies</surname><given-names>K.</given-names></name><name name-style="western"><surname>H&#228;rtel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Streng</surname><given-names>A.</given-names></name><name name-style="western"><surname>D&#246;lken</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liese</surname><given-names>J.G.</given-names></name><collab>CoPraKid Study Group</collab></person-group><article-title>Very low incidence of SARS-CoV-2, influenza and RSV but high incidence of rhino-, adeno- and endemic coronaviruses in children with acute respiratory infection in primary care pediatric practices during the second and third wave of t</article-title><source>Pediatr. Infect. Dis. J.</source><year>2022</year><volume>41</volume><fpage>e146</fpage><lpage>e148</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000003460</pub-id><pub-id pub-id-type="pmid">35175993</pub-id><pub-id pub-id-type="pmcid">PMC8919947</pub-id></element-citation></ref><ref id="B45-vaccines-13-00569"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Uyeki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name></person-group><article-title>The effects of the COVID-19 pandemic on community respiratory virus activity</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>21</volume><fpage>195</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00807-9</pub-id><pub-id pub-id-type="pmid">36253478</pub-id><pub-id pub-id-type="pmcid">PMC9574826</pub-id></element-citation></ref><ref id="B46-vaccines-13-00569"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Hammerstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aebi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barbey</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buettcher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casaulta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Egli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gebauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kahlert</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Interseasonal RSV infections in Switzerland&#8212;Rapid establishment of a clinician-led national reporting system (RSV EpiCH)</article-title><source>Swiss Med. Wkly.</source><year>2021</year><volume>151</volume><fpage>w30057</fpage><pub-id pub-id-type="doi">10.4414/SMW.2021.w30057</pub-id><pub-id pub-id-type="pmid">34499459</pub-id></element-citation></ref><ref id="B47-vaccines-13-00569"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abed</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pelletier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ruel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moisan</surname><given-names>D.</given-names></name><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peret</surname><given-names>T.C.T.</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.J.</given-names></name></person-group><article-title>Virological features and clinical manifestations associated with human metapneumovirus: A new paramyxovirus responsible for acute respiratory-tract infections in all age groups</article-title><source>J. Infect. Dis.</source><year>2002</year><volume>186</volume><fpage>1330</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1086/344319</pub-id><pub-id pub-id-type="pmid">12402203</pub-id></element-citation></ref><ref id="B48-vaccines-13-00569"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schweitzer</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Justice</surname><given-names>N.</given-names></name></person-group><article-title>Respiratory Syncytial Virus Infection in Children. [Updated 20 June 2023]</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK459215/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK459215/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation><pub-id pub-id-type="pmid">29083623</pub-id></element-citation></ref><ref id="B49-vaccines-13-00569"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bottle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Modi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aylin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Majeed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>S.</given-names></name><collab>on behalf of the Medicines for Neonates Investigator Group</collab></person-group><article-title>Risk factors for hospital admission with RSV bronchiolitis in England: A population-based birth cohort study</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e89186</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0089186</pub-id><pub-id pub-id-type="pmid">24586581</pub-id><pub-id pub-id-type="pmcid">PMC3935842</pub-id></element-citation></ref><ref id="B50-vaccines-13-00569"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Hoogen</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Doornum</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fockens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cornelissen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>W.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.</given-names></name></person-group><article-title>Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients</article-title><source>J. Infect. Dis.</source><year>2003</year><volume>188</volume><fpage>1571</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1086/379200</pub-id><pub-id pub-id-type="pmid">14624384</pub-id></element-citation></ref><ref id="B51-vaccines-13-00569"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>D.C.E.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Awang</surname><given-names>E.H.B.</given-names></name><name name-style="western"><surname>Nazri</surname><given-names>F.N.B.A.</given-names></name><name name-style="western"><surname>Maran</surname><given-names>A.K.T.</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>E.J.</given-names></name></person-group><article-title>Clinical comparison of HMPV and RSV infections in hospitalised Malaysian children: A propensity score matched study</article-title><source>Clin. Respir. J.</source><year>2024</year><volume>18</volume><fpage>e13747</fpage><pub-id pub-id-type="doi">10.1111/crj.13747</pub-id><pub-id pub-id-type="pmid">38529669</pub-id><pub-id pub-id-type="pmcid">PMC10964171</pub-id></element-citation></ref><ref id="B52-vaccines-13-00569"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadiger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sendi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Totapally</surname><given-names>B.</given-names></name></person-group><article-title>Epidemiology and Clinical Features of Human Metapneumovirus and Respiratory Syncytial Viral Infections in Children</article-title><source>Pediatr. Infect. Dis. J.</source><year>2023</year><volume>42</volume><fpage>960</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000004055</pub-id><pub-id pub-id-type="pmid">37523504</pub-id></element-citation></ref><ref id="B53-vaccines-13-00569"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Balsells</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wastnedge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>R.</given-names></name><name name-style="western"><surname>A Rasmussen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zar</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>A Rath</surname><given-names>B.</given-names></name><name name-style="western"><surname>A Madhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vaccari</surname><given-names>L.C.</given-names></name><etal/></person-group><article-title>Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis</article-title><source>J. Glob. Health</source><year>2015</year><volume>5</volume><fpage>020416</fpage><pub-id pub-id-type="doi">10.7189/jogh.05.020416</pub-id><pub-id pub-id-type="pmid">26682048</pub-id><pub-id pub-id-type="pmcid">PMC4676580</pub-id></element-citation></ref><ref id="B54-vaccines-13-00569"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papenburg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hamelin</surname><given-names>M.-&#200;.</given-names></name><name name-style="western"><surname>Ouhoummane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Carbonneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ouakki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>F.</given-names></name><name name-style="western"><surname>Robitaille</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corbeil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caouette</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frenette</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Comparison of Risk Factors for Human Metapneumovirus and Respiratory Syncytial Virus Disease Severity in Young Children</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>178</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis333</pub-id><pub-id pub-id-type="pmid">22551815</pub-id><pub-id pub-id-type="pmcid">PMC7114627</pub-id></element-citation></ref><ref id="B55-vaccines-13-00569"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Ampofo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bramley</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stockmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Grijalva</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Self</surname><given-names>W.H.</given-names></name><etal/></person-group><article-title>Community-acquired pneumonia requiring hospitalization among U.S. children</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>835</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1405870</pub-id><pub-id pub-id-type="pmid">25714161</pub-id><pub-id pub-id-type="pmcid">PMC4697461</pub-id></element-citation></ref><ref id="B56-vaccines-13-00569"><label>56.</label><element-citation publication-type="webpage"><article-title>OMS Respiratory Syncytial Virus (RSV) Disease</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/respiratory-syncytial-virus-disease" ext-link-type="uri">https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/respiratory-syncytial-virus-disease</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B57-vaccines-13-00569"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuypers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leisenring</surname><given-names>W.</given-names></name><name name-style="western"><surname>Boeckh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name></person-group><article-title>Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients</article-title><source>Biol. Blood Marrow Transpl.</source><year>2013</year><volume>19</volume><fpage>1220</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2013.05.005</pub-id><pub-id pub-id-type="pmcid">PMC3752411</pub-id><pub-id pub-id-type="pmid">23680472</pub-id></element-citation></ref><ref id="B58-vaccines-13-00569"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M.</given-names></name></person-group><article-title>Human Metapneumovirus. [Updated 17 July 2023]</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK560910/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK560910/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B59-vaccines-13-00569"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamelin</surname><given-names>M.</given-names></name><name name-style="western"><surname>C&#244;t&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laforge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lampron</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bourbeau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gilca</surname><given-names>R.</given-names></name><name name-style="western"><surname>DeSerres</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease</article-title><source>Clin. Infect. Dis.</source><year>2005</year><volume>41</volume><fpage>498</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1086/431981</pub-id><pub-id pub-id-type="pmid">16028158</pub-id></element-citation></ref><ref id="B60-vaccines-13-00569"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borchers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>L.</given-names></name></person-group><article-title>Respiratory syncytial virus&#8211;a comprehensive review</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2013</year><volume>45</volume><fpage>331</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1007/s12016-013-8368-9</pub-id><pub-id pub-id-type="pmid">23575961</pub-id><pub-id pub-id-type="pmcid">PMC7090643</pub-id></element-citation></ref><ref id="B61-vaccines-13-00569"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD Lower Respiratory Infections Collaborators</collab></person-group><article-title>Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990&#8211;2016: A systematic analysis for the Global Burden of Disease Study 2016</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>1191</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30310-4</pub-id><pub-id pub-id-type="pmid">30243584</pub-id><pub-id pub-id-type="pmcid">PMC6202443</pub-id></element-citation></ref><ref id="B62-vaccines-13-00569"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osei-Yeboah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spreeuwenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Del Riccio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Egeskov-Cavling</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>B&#248;&#229;s</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Boven</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lehtonen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bangert</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>228</volume><fpage>1539</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad189</pub-id><pub-id pub-id-type="pmid">37246742</pub-id><pub-id pub-id-type="pmcid">PMC10681866</pub-id></element-citation></ref><ref id="B63-vaccines-13-00569"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruckwardt</surname><given-names>T.J.</given-names></name></person-group><article-title>The road to approved vaccines for respiratory syncytial virus</article-title><source>npj Vaccines</source><year>2023</year><volume>8</volume><fpage>138</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00734-7</pub-id><pub-id pub-id-type="pmid">37749081</pub-id><pub-id pub-id-type="pmcid">PMC10519952</pub-id></element-citation></ref><ref id="B64-vaccines-13-00569"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curns</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Rha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lively</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Sahni</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Halasa</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Staat</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Selvarangan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Michaels</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Respiratory Syncytial Virus-Associated Hospitalizations Among Children &lt;5 Years Old: 2016 to 2020</article-title><source>Pediatrics</source><year>2024</year><volume>153</volume><fpage>e2023062574</fpage><pub-id pub-id-type="doi">10.1542/peds.2023-062574</pub-id><pub-id pub-id-type="pmid">38298053</pub-id></element-citation></ref><ref id="B65-vaccines-13-00569"><label>65.</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Houde</surname><given-names>L.</given-names></name><name name-style="western"><surname>Law</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Averin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weycker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shea</surname><given-names>K.M.</given-names></name></person-group><article-title>Annual Clinical and Economic Burden of Medically Attended Lower Respiratory Tract Illnesses Due to Respiratory Syncytial Virus Among US Infants Aged &lt; 12 Months</article-title><source>J. Infect. Dis.</source><year>2024</year><comment><italic toggle="yes">online ahead of print</italic></comment><pub-id pub-id-type="doi">10.1093/infdis/jiae544</pub-id><pub-id pub-id-type="pmid">39546626</pub-id></element-citation></ref><ref id="B66-vaccines-13-00569"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akmar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rath</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alchikh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schweiger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lucero</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Nillos</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Kyaw</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kieffer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: A systematic review and meta-analysis</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>S680</fpage><lpage>S687</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz683</pub-id><pub-id pub-id-type="pmid">32227101</pub-id></element-citation></ref><ref id="B67-vaccines-13-00569"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>C.-M.</given-names></name></person-group><article-title>Changing epidemiology of respiratory tract infection during COVID-19 pandemic</article-title><source>Antibiot.</source><year>2022</year><volume>11</volume><elocation-id>315</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11030315</pub-id><pub-id pub-id-type="pmid">35326778</pub-id><pub-id pub-id-type="pmcid">PMC8944752</pub-id></element-citation></ref><ref id="B68-vaccines-13-00569"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente</surname><given-names>I.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vittorini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pallotta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sinatti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mammarella</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rancitelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Balsano</surname><given-names>C.</given-names></name></person-group><article-title>Fall of viral and bacterial pneumonia hospitalizations following COVID-19 pandemic mitigation strategies: A Central Italian Region retrospective study</article-title><source>Intern. Emerg. Med.</source><year>2023</year><volume>18</volume><fpage>1181</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1007/s11739-023-03213-y</pub-id><pub-id pub-id-type="pmid">36750536</pub-id><pub-id pub-id-type="pmcid">PMC9904871</pub-id></element-citation></ref><ref id="B69-vaccines-13-00569"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoukat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bawden</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>R&#246;st</surname><given-names>G.</given-names></name><name name-style="western"><surname>LeBlanc</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Galvani</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Moghadas</surname><given-names>S.M.</given-names></name></person-group><article-title>Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>1768</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.02.041</pub-id><pub-id pub-id-type="pmid">38368226</pub-id></element-citation></ref><ref id="B70-vaccines-13-00569"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghadas</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Shoukat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bawden</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Galvani</surname><given-names>A.P.</given-names></name></person-group><article-title>Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>1328</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad658</pub-id><pub-id pub-id-type="pmid">38035791</pub-id><pub-id pub-id-type="pmcid">PMC11093660</pub-id></element-citation></ref><ref id="B71-vaccines-13-00569"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoukat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Galvani</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Halperin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Moghadasa</surname><given-names>S.M.</given-names></name></person-group><article-title>Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: A simulation study</article-title><source>Lancet Reg. Health-Am.</source><year>2023</year><volume>28</volume><fpage>100629</fpage><pub-id pub-id-type="doi">10.1016/j.lana.2023.100629</pub-id><pub-id pub-id-type="pmid">38026446</pub-id><pub-id pub-id-type="pmcid">PMC10663690</pub-id></element-citation></ref><ref id="B72-vaccines-13-00569"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mac</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sumner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duchesne-Belanger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stirling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tunis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>B.</given-names></name></person-group><article-title>Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review</article-title><source>Pediatrics</source><year>2019</year><volume>143</volume><fpage>e20184064</fpage><pub-id pub-id-type="doi">10.1542/peds.2018-4064</pub-id><pub-id pub-id-type="pmid">31040196</pub-id></element-citation></ref><ref id="B73-vaccines-13-00569"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Szilagyi</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Staat</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Iwane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prill</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.V.</given-names></name></person-group><article-title>New Vaccine Surveillance Network, Burden of human metapneumovirus infection in young children</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1204630</pub-id><pub-id pub-id-type="pmid">23406028</pub-id><pub-id pub-id-type="pmcid">PMC3662802</pub-id></element-citation></ref><ref id="B74-vaccines-13-00569"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manoha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bour</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fournel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tiv</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pothier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Astruc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aho-Gl&#233;l&#233;</surname><given-names>L.S.</given-names></name></person-group><article-title>Human metapneumovirus in patients hospitalized with acute respiratory infections: A metaanalysis</article-title><source>J. Clin. Virol.</source><year>2016</year><volume>81</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2016.05.015</pub-id><pub-id pub-id-type="pmid">27337518</pub-id><pub-id pub-id-type="pmcid">PMC7106388</pub-id></element-citation></ref><ref id="B75-vaccines-13-00569"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Incidence of viral infection detected by PCR and real-time PCR in childhood community-acquired pneumonia: A meta-analysis. Respirology</article-title><source>Respirology</source><year>2015</year><volume>20</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/resp.12472</pub-id><pub-id pub-id-type="pmid">25615588</pub-id><pub-id pub-id-type="pmcid">PMC7169115</pub-id></element-citation></ref><ref id="B76-vaccines-13-00569"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nandhini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sujatha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dhodapkar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tamilarasu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krishnamurthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biswal</surname><given-names>N.</given-names></name></person-group><article-title>Prevalence of Human metapneumovirus infection among patients with influenza-like illness: Report from a Tertiary Care Centre, Southern India</article-title><source>Indian. J. Med. Microbiol.</source><year>2016</year><volume>34</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.4103/0255-0857.174117</pub-id><pub-id pub-id-type="pmid">26776115</pub-id></element-citation></ref><ref id="B77-vaccines-13-00569"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name></person-group><article-title>Epidemiology and genotypic diversity of human metapneumovirus in paediatric patients with acute respiratory infection in Beijing, China</article-title><source>Virol. J.</source><year>2021</year><volume>18</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/s12985-021-01508-0</pub-id><pub-id pub-id-type="pmid">33602245</pub-id><pub-id pub-id-type="pmcid">PMC7890387</pub-id></element-citation></ref><ref id="B78-vaccines-13-00569"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oketch</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kamau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Otieno</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Agoti</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Nokes</surname><given-names>D.J.</given-names></name></person-group><article-title>Human metapneumovirus prevalence and patterns of subgroup persistence identified through surveillance of pediatric pneumonia hospital admissions in coastal Kenya, 2007&#8211;2016</article-title><source>BMC Infect. Dis.</source><year>2019</year><volume>19</volume><elocation-id>757</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-4381-9</pub-id><pub-id pub-id-type="pmid">31470805</pub-id><pub-id pub-id-type="pmcid">PMC6716807</pub-id></element-citation></ref><ref id="B79-vaccines-13-00569"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loubet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lenzi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galtier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lain&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lesieur</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vanhems</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>X.</given-names></name><name name-style="western"><surname>Postil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amour</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Characteristics of human metapneumovirus infection in adults hospitalized for community-acquired influenza-like illness in France, 2012&#8211;2018: A retrospective observational study</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><fpage>127.e1</fpage><lpage>127.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.005</pub-id><pub-id pub-id-type="pmcid">PMC7195031</pub-id><pub-id pub-id-type="pmid">32283266</pub-id></element-citation></ref><ref id="B80-vaccines-13-00569"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inagaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kitano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Onaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kitagawa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Masuo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S.</given-names></name></person-group><article-title>The epidemiology of admission-requiring pediatric respiratory infections in a japanese community hospital using multiplex PCR</article-title><source>Jpn. J. Infect. Dis.</source><year>2021</year><volume>74</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.7883/yoken.JJID.2020.154</pub-id><pub-id pub-id-type="pmid">32611977</pub-id></element-citation></ref><ref id="B81-vaccines-13-00569"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aminisani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jelley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.S.</given-names></name></person-group><article-title>The Burden of Human Metapneumovirus- and Influenza-Associated Hospitalizations in Adults in New Zealand, 2012&#8211;2015</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>230</volume><fpage>933</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiae064</pub-id><pub-id pub-id-type="pmid">38349230</pub-id></element-citation></ref><ref id="B82-vaccines-13-00569"><label>82.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Plemper</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Melikyan</surname><given-names>G.B.</given-names></name></person-group><article-title>Membrane Fusion</article-title><source>Encyclopedia of Biological Chemistry</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2013</year><fpage>36</fpage><lpage>43</lpage></element-citation></ref><ref id="B83-vaccines-13-00569"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>J.</given-names></name><name name-style="western"><surname>Delos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brecher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schornberg</surname><given-names>K.</given-names></name></person-group><article-title>Structures and mechanisms of viral membrane fusion proteins: Multiple variations on a common theme</article-title><source>Crit. Rev. Biochem. Mol. Biol.</source><year>2008</year><volume>43</volume><fpage>189</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1080/10409230802058320</pub-id><pub-id pub-id-type="pmid">18568847</pub-id><pub-id pub-id-type="pmcid">PMC2649671</pub-id></element-citation></ref><ref id="B84-vaccines-13-00569"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mas</surname><given-names>V.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.</given-names></name></person-group><article-title>Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.09.045</pub-id><pub-id pub-id-type="pmid">27692522</pub-id><pub-id pub-id-type="pmcid">PMC5189713</pub-id></element-citation></ref><ref id="B85-vaccines-13-00569"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rush</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gingerich</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Royer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>J.J.</given-names></name></person-group><article-title>Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2203326119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2203326119</pub-id><pub-id pub-id-type="pmid">35696580</pub-id><pub-id pub-id-type="pmcid">PMC9231621</pub-id></element-citation></ref><ref id="B86-vaccines-13-00569"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardetzky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>R.</given-names></name></person-group><article-title>Activation of paramyxovirus membrane fusion and virus entry</article-title><source>Curr. Opin. Virol.</source><year>2014</year><volume>5</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2014.01.005</pub-id><pub-id pub-id-type="pmid">24530984</pub-id><pub-id pub-id-type="pmcid">PMC4028362</pub-id></element-citation></ref><ref id="B87-vaccines-13-00569"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Reyes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bego&#241;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruiz-Arg&#252; Ello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Barreno</surname><given-names>B.</given-names></name><name name-style="western"><surname>Calder</surname><given-names>L.</given-names></name><name name-style="western"><surname>L&#243;Pez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Albar</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Skehel</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>J.A.</given-names></name></person-group><article-title>Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>9859</fpage><lpage>9864</lpage><pub-id pub-id-type="doi">10.1073/pnas.151098198</pub-id><pub-id pub-id-type="pmid">11493675</pub-id><pub-id pub-id-type="pmcid">PMC55543</pub-id></element-citation></ref><ref id="B88-vaccines-13-00569"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Budz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G.</given-names></name></person-group><article-title>Proteolytic activation of respiratory syncytial virus fusion protein</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>31642</fpage><lpage>31650</lpage><pub-id pub-id-type="doi">10.1074/jbc.M102633200</pub-id><pub-id pub-id-type="pmid">11418598</pub-id></element-citation></ref><ref id="B89-vaccines-13-00569"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Klenow</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Golding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khurana</surname><given-names>S.</given-names></name></person-group><article-title>Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain</article-title><source>EMBO Mol. Med.</source><year>2022</year><volume>14</volume><fpage>e13847</fpage><pub-id pub-id-type="doi">10.15252/emmm.202013847</pub-id><pub-id pub-id-type="pmid">34750984</pub-id><pub-id pub-id-type="pmcid">PMC8749483</pub-id></element-citation></ref><ref id="B90-vaccines-13-00569"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battles</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Respiratory syncytial virus entry and how to block it</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>233</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0149-x</pub-id><pub-id pub-id-type="pmid">30723301</pub-id><pub-id pub-id-type="pmcid">PMC7096974</pub-id></element-citation></ref><ref id="B91-vaccines-13-00569"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirogane</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakatsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kikuta</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yanagi</surname><given-names>Y.</given-names></name></person-group><article-title>Efficient multiplication of human metapneumovirus in Vero cells 1154 expressing the transmembrane serine protease TMPRSS2</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>8942</fpage><lpage>8946</lpage><pub-id pub-id-type="doi">10.1128/JVI.00676-08</pub-id><pub-id pub-id-type="pmid">18562527</pub-id><pub-id pub-id-type="pmcid">PMC2519639</pub-id></element-citation></ref><ref id="B92-vaccines-13-00569"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakatsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kikuta</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yanagi</surname><given-names>Y.</given-names></name></person-group><article-title>Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1528</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01708-9</pub-id><pub-id pub-id-type="pmid">29142300</pub-id><pub-id pub-id-type="pmcid">PMC5688127</pub-id></element-citation></ref><ref id="B93-vaccines-13-00569"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schowalter</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Dutch</surname><given-names>R.E.</given-names></name></person-group><article-title>Characterization of Human Metapneumovirus F Protein-Promoted Membrane Fusion: Critical Roles for Proteolytic Processing and Low pH</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>10931</fpage><lpage>10941</lpage><pub-id pub-id-type="doi">10.1128/JVI.01287-06</pub-id><pub-id pub-id-type="pmid">16971452</pub-id><pub-id pub-id-type="pmcid">PMC1642150</pub-id></element-citation></ref><ref id="B94-vaccines-13-00569"><label>94.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>G.D.</given-names></name></person-group><article-title>Paramyxoviridae</article-title><source>Fields Virology</source><edition>6th ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Knipe</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Howley</surname><given-names>P.M.</given-names></name></person-group><publisher-name>Wolters Kluwer/LippincottWilliams &amp; Wilkins</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B95-vaccines-13-00569"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>J.J.</given-names></name></person-group><article-title>Antibody Epitopes of Pneumovirus Fusion Proteins</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>2778</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02778</pub-id><pub-id pub-id-type="pmid">31849961</pub-id><pub-id pub-id-type="pmcid">PMC6895023</pub-id></element-citation></ref><ref id="B96-vaccines-13-00569"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plemper</surname><given-names>R.K.</given-names></name></person-group><article-title>Structural insight into paramyxovirus and pneumovirus entry inhibition</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>342</elocation-id><pub-id pub-id-type="doi">10.3390/v12030342</pub-id><pub-id pub-id-type="pmid">32245118</pub-id><pub-id pub-id-type="pmcid">PMC7150754</pub-id></element-citation></ref><ref id="B97-vaccines-13-00569"><label>97.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>EMA</collab></person-group><article-title>Beyfortus. European Medicines Agency</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B98-vaccines-13-00569"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Castellanos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ngwuta</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moin</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors</article-title><source>Sci. Immunol.</source><year>2016</year><volume>1</volume><fpage>eaaj1879</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aaj1879</pub-id><pub-id pub-id-type="pmid">28111638</pub-id><pub-id pub-id-type="pmcid">PMC5244814</pub-id></element-citation></ref><ref id="B99-vaccines-13-00569"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mclellan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L.</given-names></name></person-group><article-title>Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>339</fpage><lpage>349.e5</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.01.005</pub-id><pub-id pub-id-type="pmid">29396163</pub-id><pub-id pub-id-type="pmcid">PMC6005179</pub-id></element-citation></ref><ref id="B100-vaccines-13-00569"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zar</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Simoes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramilo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Senders</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shepard</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Laoprasopwattana</surname><given-names>K.</given-names></name><name name-style="western"><surname>Piedrahita</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>J.M.N.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>166. A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants</article-title><source>Open Forum Infect. Dis.</source><year>2025</year><volume>12</volume><fpage>ofae631.003</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofae631.003</pub-id></element-citation></ref><ref id="B101-vaccines-13-00569"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hemming</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Pfarr</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-C.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Grady</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus</article-title><source>J. Infect. Dis.</source><year>1997</year><volume>176</volume><fpage>1215</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1086/514115</pub-id><pub-id pub-id-type="pmid">9359721</pub-id></element-citation></ref><ref id="B102-vaccines-13-00569"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Jardetzky</surname><given-names>T.S.</given-names></name></person-group><article-title>Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus</article-title><source>Nat. Microbiol.</source><year>2017</year><volume>2</volume><elocation-id>16272</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.272</pub-id><pub-id pub-id-type="pmid">28134915</pub-id><pub-id pub-id-type="pmcid">PMC5308794</pub-id></element-citation></ref><ref id="B103-vaccines-13-00569"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuster</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Wadia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.V.</given-names></name></person-group><article-title>A Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Efficacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>211</volume><fpage>216</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu307</pub-id><pub-id pub-id-type="pmid">24864121</pub-id><pub-id pub-id-type="pmcid">PMC4342691</pub-id></element-citation></ref><ref id="B104-vaccines-13-00569"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Suryadevara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Handal</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Trivette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carnahan</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Jardetzky</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode</article-title><source>Cell Host Microbe</source><year>2023</year><volume>31</volume><fpage>1288</fpage><lpage>1300.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2023.07.002</pub-id><pub-id pub-id-type="pmid">37516111</pub-id><pub-id pub-id-type="pmcid">PMC10527986</pub-id></element-citation></ref><ref id="B105-vaccines-13-00569"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulbrandt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kiener</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Suzich</surname><given-names>J.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>M.P.</given-names></name></person-group><article-title>Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus</article-title><source>J. Gen. Virol.</source><year>2008</year><volume>89</volume><fpage>3113</fpage><lpage>3118</lpage><pub-id pub-id-type="doi">10.1099/vir.0.2008/005199-0</pub-id><pub-id pub-id-type="pmid">19008400</pub-id><pub-id pub-id-type="pmcid">PMC2885031</pub-id></element-citation></ref><ref id="B106-vaccines-13-00569"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Nahas</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Cosmi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Minnier</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV crossneutralizing epitopes</article-title><source>MAbs</source><year>2019</year><volume>11</volume><fpage>1415</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1080/19420862.2019.1654304</pub-id><pub-id pub-id-type="pmid">31402751</pub-id><pub-id pub-id-type="pmcid">PMC6816417</pub-id></element-citation></ref><ref id="B107-vaccines-13-00569"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mousa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Binshtein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Human</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>G.</given-names></name><name name-style="western"><surname>Doranz</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Ohi</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J.E.</given-names></name></person-group><article-title>Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1006837</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006837</pub-id><pub-id pub-id-type="pmid">29470533</pub-id><pub-id pub-id-type="pmcid">PMC5823459</pub-id></element-citation></ref><ref id="B108-vaccines-13-00569"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>J.J.</given-names></name></person-group><article-title>Structural basis for respiratory syncytial virus and human metapneumovirus neutralization</article-title><source>Curr. Opin. Virol.</source><year>2023</year><volume>61</volume><fpage>101337</fpage><pub-id pub-id-type="doi">10.1016/j.coviro.2023.101337</pub-id><pub-id pub-id-type="pmid">37544710</pub-id><pub-id pub-id-type="pmcid">PMC10421620</pub-id></element-citation></ref><ref id="B109-vaccines-13-00569"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name></person-group><article-title>Neutralising antibodies against human metapneumovirus</article-title><source>Lancet Microbe</source><year>2023</year><volume>4</volume><fpage>e732</fpage><lpage>e744</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(23)00134-9</pub-id><pub-id pub-id-type="pmid">37499668</pub-id></element-citation></ref><ref id="B110-vaccines-13-00569"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rush</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Palomo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Pickens</surname><given-names>W.</given-names></name><name name-style="western"><surname>M&#225;s</surname><given-names>V.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>1299</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-28931-3</pub-id><pub-id pub-id-type="pmid">35288548</pub-id><pub-id pub-id-type="pmcid">PMC8921277</pub-id></element-citation></ref><ref id="B111-vaccines-13-00569"><label>111.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>PATH</collab></person-group><article-title>RSV Vaccine and mAb Snapshot</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.path.org/our-impact/resources/rsv-vaccine-and-mab-snapshot/" ext-link-type="uri">https://www.path.org/our-impact/resources/rsv-vaccine-and-mab-snapshot/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B112-vaccines-13-00569"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sales</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name></person-group><article-title>Respiratory syncytial virus vaccine: Is it coming?</article-title><source>Paediatr. Child. Health</source><year>2003</year><volume>8</volume><fpage>605</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1093/pch/8.10.605</pub-id><pub-id pub-id-type="pmid">20019850</pub-id><pub-id pub-id-type="pmcid">PMC2795278</pub-id></element-citation></ref><ref id="B113-vaccines-13-00569"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Canchola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pyles</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>R.</given-names></name></person-group><article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title><source>Am. J. Epidemiol.</source><year>1969</year><volume>89</volume><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120955</pub-id><pub-id pub-id-type="pmid">4305198</pub-id></element-citation></ref><ref id="B114-vaccines-13-00569"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazur</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Terstappen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baral</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bardaj&#237;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beutels</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>e2</fpage><lpage>e21</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00291-2</pub-id><pub-id pub-id-type="pmid">35952703</pub-id><pub-id pub-id-type="pmcid">PMC9896921</pub-id></element-citation></ref><ref id="B115-vaccines-13-00569"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ison</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-G.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Martinon-Torres</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>van Zyl-Smit</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Campora</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dezutter</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2209604</pub-id><pub-id pub-id-type="pmid">36791160</pub-id></element-citation></ref><ref id="B116-vaccines-13-00569"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ison</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Papi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Athan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Martinon-Torres</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>van Zyl-Smit</surname><given-names>R.N.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>78</volume><fpage>1732</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1093/cid/ciae010</pub-id><pub-id pub-id-type="pmid">38253338</pub-id><pub-id pub-id-type="pmcid">PMC11175669</pub-id></element-citation></ref><ref id="B117-vaccines-13-00569"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Llapur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doreski</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Ilangovan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>1465</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2213836</pub-id><pub-id pub-id-type="pmid">37018468</pub-id></element-citation></ref><ref id="B118-vaccines-13-00569"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Munjal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Pahud</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Llapur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Radley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shittu</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>1451</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2216480</pub-id><pub-id pub-id-type="pmid">37018474</pub-id></element-citation></ref><ref id="B119-vaccines-13-00569"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baqui</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Doreski</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Perez-Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Monroy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>C.J.A.</given-names></name><name name-style="western"><surname>Ujiie</surname><given-names>M.</given-names></name><name name-style="western"><surname>R&#228;met</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>2233</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2307079</pub-id><pub-id pub-id-type="pmid">38091530</pub-id></element-citation></ref><ref id="B120-vaccines-13-00569"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapikian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shvedoff</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>C.</given-names></name></person-group><article-title>An epidemiologic study of altered clinical reactivity to respiratory syncytial (rs) virus infection in children previously vaccinated with an inactivated rs virus vaccine</article-title><source>Am. J. Epidemiol.</source><year>1969</year><volume>89</volume><fpage>405</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120954</pub-id><pub-id pub-id-type="pmid">4305197</pub-id></element-citation></ref><ref id="B121-vaccines-13-00569"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>G.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hemming</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name></person-group><article-title>Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine</article-title><source>J. Clin. Microbiol.</source><year>1986</year><volume>24</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1128/jcm.24.2.197-202.1986</pub-id><pub-id pub-id-type="pmid">3755730</pub-id><pub-id pub-id-type="pmcid">PMC268874</pub-id></element-citation></ref><ref id="B122-vaccines-13-00569"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>E.</given-names></name></person-group><article-title>Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity</article-title><source>J. Clin. Microbiol.</source><year>1988</year><volume>26</volume><fpage>1595</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1128/jcm.26.8.1595-1597.1988</pub-id><pub-id pub-id-type="pmid">2459154</pub-id><pub-id pub-id-type="pmcid">PMC266671</pub-id></element-citation></ref><ref id="B123-vaccines-13-00569"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>G.</given-names></name><name name-style="western"><surname>Exner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Regele</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lirman</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Rabold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Karp</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>A role for immune complexes in enhanced respiratory syncytial virus disease</article-title><source>J. Exp. Med.</source><year>2002</year><volume>196</volume><fpage>859</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1084/jem.20020781</pub-id><pub-id pub-id-type="pmid">12235218</pub-id><pub-id pub-id-type="pmcid">PMC2194058</pub-id></element-citation></ref><ref id="B124-vaccines-13-00569"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Erdman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.</given-names></name></person-group><article-title>Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>2852</fpage><lpage>2860</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.5.2852-2860.1996</pub-id><pub-id pub-id-type="pmid">8627759</pub-id><pub-id pub-id-type="pmcid">PMC190142</pub-id></element-citation></ref><ref id="B125-vaccines-13-00569"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakuk</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Soike</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brideau</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Zaya</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Wathen</surname><given-names>M.W.</given-names></name></person-group><article-title>A Human Respiratory Syncytial Virus (RSV) Primate Model of Enhanced Pulmonary Pathology Induced with a Formalin-Inactivated RSV Vaccine but Not a Recombinant FG Subunit Vaccine</article-title><source>J. Infect. Dis.</source><year>1993</year><volume>167</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1093/infdis/167.3.553</pub-id><pub-id pub-id-type="pmid">8440926</pub-id></element-citation></ref><ref id="B126-vaccines-13-00569"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>S.</given-names></name></person-group><article-title>Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine</article-title><source>J. Gen. Virol.</source><year>2001</year><volume>82</volume><fpage>2881</fpage><lpage>2888</lpage><pub-id pub-id-type="pmid">11714962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/0022-1317-82-12-2881</pub-id></element-citation></ref><ref id="B127-vaccines-13-00569"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schelegle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Woolums</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Friebertshauser</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>R.</given-names></name></person-group><article-title>A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>1225</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)80123-0</pub-id><pub-id pub-id-type="pmid">9682383</pub-id></element-citation></ref><ref id="B128-vaccines-13-00569"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafique</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haan</surname><given-names>A.</given-names></name></person-group><article-title>de Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.054</pub-id><pub-id pub-id-type="pmid">22120195</pub-id></element-citation></ref><ref id="B129-vaccines-13-00569"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hruska</surname><given-names>J.</given-names></name></person-group><article-title>Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein</article-title><source>J. Virol.</source><year>1983</year><volume>47</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1128/jvi.47.1.171-177.1983</pub-id><pub-id pub-id-type="pmid">6345804</pub-id><pub-id pub-id-type="pmcid">PMC255221</pub-id></element-citation></ref><ref id="B130-vaccines-13-00569"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brandriss</surname><given-names>M.</given-names></name></person-group><article-title>Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies</article-title><source>Infect. Immun.</source><year>1984</year><volume>43</volume><fpage>756</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1128/iai.43.2.756-758.1984</pub-id><pub-id pub-id-type="pmid">6363300</pub-id><pub-id pub-id-type="pmcid">PMC264366</pub-id></element-citation></ref><ref id="B131-vaccines-13-00569"><label>131.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Product Approval Information_Palivizumab</article-title><year>1998</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/palimed061998L.htm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/palimed061998L.htm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B132-vaccines-13-00569"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The IMpact-RSV Study Group</collab></person-group><article-title>Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants</article-title><source>Pediatrics</source><year>1998</year><volume>102</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1542/peds.102.3.531</pub-id><pub-id pub-id-type="pmid">9724660</pub-id></element-citation></ref><ref id="B133-vaccines-13-00569"><label>133.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>FDA Approves New Drug to Prevent RSV in Babies and Toddlers</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B134-vaccines-13-00569"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Power</surname><given-names>U.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rietveld</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Swart</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corvaia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bouveret-Le-Cam</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults</article-title><source>J. Infect. Dis.</source><year>2001</year><volume>184</volume><fpage>1456</fpage><lpage>1460</lpage><pub-id pub-id-type="doi">10.1086/324426</pub-id><pub-id pub-id-type="pmid">11709789</pub-id></element-citation></ref><ref id="B135-vaccines-13-00569"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groothuis</surname><given-names>J.</given-names></name><name name-style="western"><surname>King</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hogerman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paradiso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Simoes</surname><given-names>E.</given-names></name></person-group><article-title>Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia</article-title><source>J. Infect. Dis.</source><year>1998</year><volume>177</volume><fpage>467</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1086/517377</pub-id><pub-id pub-id-type="pmid">9466539</pub-id></element-citation></ref><ref id="B136-vaccines-13-00569"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simoes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ohlsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sales</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name></person-group><article-title>Respiratory syncytial virus vaccine: A systematic overview with emphasis on respiratory syncytial virus subunit vaccines</article-title><source>Vaccine</source><year>2001</year><volume>20</volume><fpage>954</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00388-7</pub-id><pub-id pub-id-type="pmid">11738763</pub-id></element-citation></ref><ref id="B137-vaccines-13-00569"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piedra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamblett</surname><given-names>N.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>R.</given-names></name><name name-style="western"><surname>Palacio</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oermann</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hiatt</surname><given-names>P.W.</given-names></name></person-group><article-title>Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: A multi-center trial in children with cystic fibrosis</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>2448</fpage><lpage>2460</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00098-7</pub-id><pub-id pub-id-type="pmid">12744878</pub-id></element-citation></ref><ref id="B138-vaccines-13-00569"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Glezen</surname><given-names>W.</given-names></name></person-group><article-title>Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>3465</fpage><lpage>3467</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00352-9</pub-id><pub-id pub-id-type="pmid">12850361</pub-id></element-citation></ref><ref id="B139-vaccines-13-00569"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>G.B.E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Srivatsan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1126/science.1243283</pub-id><pub-id pub-id-type="pmid">24179220</pub-id><pub-id pub-id-type="pmcid">PMC4461862</pub-id></element-citation></ref><ref id="B140-vaccines-13-00569"><label>140.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>US Food and Drug Administration. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B141-vaccines-13-00569"><label>141.</label><element-citation publication-type="webpage"><article-title>European Medicines Agency Arexvy: Recombinant Respiratory Syncytial Virus Pre-Fusion F Protein, Adjuvanted with AS01E</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B142-vaccines-13-00569"><label>142.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B143-vaccines-13-00569"><label>143.</label><element-citation publication-type="webpage"><article-title>European Medicines Agency Abrysvo: European Medicines Agency</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B144-vaccines-13-00569"><label>144.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>GSK</collab></person-group><article-title>Package Insert&#8212;AREXVY</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/167805/download" ext-link-type="uri">https://www.fda.gov/media/167805/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B145-vaccines-13-00569"><label>145.</label><element-citation publication-type="gov"><article-title>Summary Basis for Regulatory Action-AREXVY</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/168519/download?attachment" ext-link-type="uri">https://www.fda.gov/media/168519/download?attachment</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B146-vaccines-13-00569"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Steenackers</surname><given-names>K.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fogarty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Kerwin</surname><given-names>E.</given-names></name><name name-style="western"><surname>David</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Fissette</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>227</volume><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac327</pub-id><pub-id pub-id-type="pmid">35904987</pub-id><pub-id pub-id-type="pmcid">PMC10044090</pub-id></element-citation></ref><ref id="B147-vaccines-13-00569"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dieussaert</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Luik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seidl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stegmann</surname><given-names>J.-U.</given-names></name><name name-style="western"><surname>Swamy</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name></person-group><article-title>RSV Prefusion F Protein&#8211;Based Maternal Vaccine&#8212;Preterm Birth and Other Outcomes</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>390</volume><fpage>1009</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2305478</pub-id><pub-id pub-id-type="pmid">38477988</pub-id></element-citation></ref><ref id="B148-vaccines-13-00569"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ylisastigui</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Takazawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yono</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ervin</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Fogarty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eckermann</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>230</volume><fpage>e102</fpage><lpage>e110</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiad546</pub-id><pub-id pub-id-type="pmid">39052726</pub-id><pub-id pub-id-type="pmcid">PMC11272088</pub-id></element-citation></ref><ref id="B149-vaccines-13-00569"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montenegro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Llorach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aguirre</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuriyakose</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Descamps</surname><given-names>D.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hulstr&#248;m</surname><given-names>V.</given-names></name></person-group><article-title>Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein-Based Candidate Vaccine (RSVPreF3 OA) When Co-Administered with a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Ph</article-title><source>Clin. Infect. Dis.</source><year>2024</year><pub-id pub-id-type="doi">10.1093/cid/ciad786</pub-id><pub-id pub-id-type="pmid">38189778</pub-id></element-citation></ref><ref id="B150-vaccines-13-00569"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buynak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>K.</given-names></name><name name-style="western"><surname>DeAtkine</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Usdan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bhavsar</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#233;rard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kuznetsova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jayadev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Amare</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged &#8805; 65</article-title><source>Infect. Dis. Ther.</source><year>2024</year><volume>13</volume><fpage>1789</fpage><lpage>1805</lpage><pub-id pub-id-type="doi">10.1007/s40121-024-00985-4</pub-id><pub-id pub-id-type="pmid">38981954</pub-id><pub-id pub-id-type="pmcid">PMC11266338</pub-id></element-citation></ref><ref id="B151-vaccines-13-00569"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>R.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>S.</given-names></name><name name-style="western"><surname>Labrador</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loubet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Natalini Mart&#237;nez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mor&#237;&#241;igo</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Vera</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>R&#228;met</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rebollo-Rodrigo</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>79</volume><fpage>1088</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1093/cid/ciae365</pub-id><pub-id pub-id-type="pmid">39099085</pub-id><pub-id pub-id-type="pmcid">PMC11478588</pub-id></element-citation></ref><ref id="B152-vaccines-13-00569"><label>152.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Pfizer</collab></person-group><article-title>Package Insert&#8212;ABRYSVO</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/168889/download" ext-link-type="uri">https://www.fda.gov/media/168889/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B153-vaccines-13-00569"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>A Scott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>A Swanson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Radley</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>1357</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab612</pub-id><pub-id pub-id-type="pmid">34932102</pub-id><pub-id pub-id-type="pmcid">PMC9016447</pub-id></element-citation></ref><ref id="B154-vaccines-13-00569"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moodley</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jaques</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>A Swanson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maddur</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Loschko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine with and Without Adjuvant in Healthy Older Adults</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>226</volume><fpage>2054</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac189</pub-id><pub-id pub-id-type="pmid">35543281</pub-id><pub-id pub-id-type="pmcid">PMC9749002</pub-id></element-citation></ref><ref id="B155-vaccines-13-00569"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmoele-Thoma</surname><given-names>B.</given-names></name></person-group><article-title>Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>2377</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116154</pub-id><pub-id pub-id-type="pmid">35731653</pub-id></element-citation></ref><ref id="B156-vaccines-13-00569"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.</given-names></name><name name-style="western"><surname>Center</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Tita</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Radley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Houghton</surname><given-names>J.</given-names></name><name name-style="western"><surname>McGrory</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Gomme</surname><given-names>E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Respiratory, Prefusion F Protein&#8211;Based Syncytial Virus Immunization in Pregnancy</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>1615</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2106062</pub-id><pub-id pub-id-type="pmid">35476650</pub-id></element-citation></ref><ref id="B157-vaccines-13-00569"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults with Concomitant Inactivated Influenza Vaccine</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>2056</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab611</pub-id><pub-id pub-id-type="pmid">34931667</pub-id><pub-id pub-id-type="pmcid">PMC9200152</pub-id></element-citation></ref><ref id="B158-vaccines-13-00569"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fitz-Patrick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chelani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Radley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered with a Tetanus, Diphtheria, and Acellular Pertussis Vaccine</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>2077</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab505</pub-id><pub-id pub-id-type="pmid">34637519</pub-id><pub-id pub-id-type="pmcid">PMC9200146</pub-id></element-citation></ref><ref id="B159-vaccines-13-00569"><label>159.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Pfizer</collab></person-group><article-title>A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (MONET)</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05842967?cond=NCT05842967&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05842967?cond=NCT05842967&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B160-vaccines-13-00569"><label>160.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Pfizer</collab></person-group><article-title>A Study to Learn About the Vaccine RSVpreF In Pregnant Participants with HIV and Their Infants (MORISOT)</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06325657?cond=NCT06325657&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06325657?cond=NCT06325657&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B161-vaccines-13-00569"><label>161.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIAID</collab></person-group><article-title>The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06551506?cond=NCT06551506&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06551506?cond=NCT06551506&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B162-vaccines-13-00569"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name></person-group><article-title>Live-Attenuated Respiratory Syncytial Virus Vaccines</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2013</year><volume>372</volume><fpage>259</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-38919-1_13</pub-id><pub-id pub-id-type="pmid">24362694</pub-id><pub-id pub-id-type="pmcid">PMC4794267</pub-id></element-citation></ref><ref id="B163-vaccines-13-00569"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shinozaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fleet</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karzon</surname><given-names>D.</given-names></name></person-group><article-title>Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants</article-title><source>J. Pediatr.</source><year>1976</year><volume>88</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(76)81044-X</pub-id><pub-id pub-id-type="pmid">178852</pub-id></element-citation></ref><ref id="B164-vaccines-13-00569"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedewald</surname><given-names>W.</given-names></name><name name-style="western"><surname>Forsyth</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gharpure</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.</given-names></name></person-group><article-title>Low-temperature-grown RS virus in adult volunteers</article-title><source>JAMA</source><year>1968</year><volume>204</volume><fpage>690</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1001/jama.1968.03140210044011</pub-id><pub-id pub-id-type="pmid">5694511</pub-id></element-citation></ref><ref id="B165-vaccines-13-00569"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>P.</given-names></name><name name-style="western"><surname>Woodend</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name></person-group><article-title>Temperature-Sensitive Mutants of Respiratory Syncytial Virus: In-Vivo Studies in Hamsters</article-title><source>J. Infect. Dis.</source><year>1970</year><volume>122</volume><fpage>501</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1093/infdis/122.6.501</pub-id><pub-id pub-id-type="pmid">5489074</pub-id></element-citation></ref><ref id="B166-vaccines-13-00569"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowe</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>London</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>More</surname><given-names>S.</given-names></name></person-group><article-title>Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis</article-title><source>Vaccine</source><year>1994</year><volume>12</volume><fpage>691</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)90218-6</pub-id><pub-id pub-id-type="pmid">8091846</pub-id></element-citation></ref><ref id="B167-vaccines-13-00569"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>P.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name></person-group><article-title>New generation live vaccines against human respiratory syncytial virus designed by reverse genetics</article-title><source>Proc. Am. Thorac. Soc.</source><year>2005</year><volume>2</volume><fpage>166</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1513/pats.200501-011AW</pub-id><pub-id pub-id-type="pmid">16113487</pub-id><pub-id pub-id-type="pmcid">PMC2713317</pub-id></element-citation></ref><ref id="B168-vaccines-13-00569"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Bukreyev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Firestone</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Claire</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name></person-group><article-title>Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees</article-title><source>J. Virol.</source><year>1999</year><volume>73</volume><fpage>3438</fpage><lpage>3442</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.4.3438-3442.1999</pub-id><pub-id pub-id-type="pmid">10074199</pub-id><pub-id pub-id-type="pmcid">PMC104109</pub-id></element-citation></ref><ref id="B169-vaccines-13-00569"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitehead</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>M.</given-names></name><name name-style="western"><surname>Firestone</surname><given-names>C.</given-names></name><name name-style="western"><surname>St Claire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>W.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.</given-names></name></person-group><article-title>Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates</article-title><source>J. Virol.</source><year>1999</year><volume>73</volume><fpage>9773</fpage><lpage>9780</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.12.9773-9780.1999</pub-id><pub-id pub-id-type="pmid">10559287</pub-id><pub-id pub-id-type="pmcid">PMC113024</pub-id></element-citation></ref><ref id="B170-vaccines-13-00569"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermingham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.</given-names></name></person-group><article-title>The M2&#8211;2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>11259</fpage><lpage>11264</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.20.11259</pub-id><pub-id pub-id-type="pmid">10500164</pub-id><pub-id pub-id-type="pmcid">PMC18021</pub-id></element-citation></ref><ref id="B171-vaccines-13-00569"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Atwell</surname><given-names>J.</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Muresan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perlowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Libous</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yogev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Live-attenuated vaccines prevent respiratory syncytial virus-associated illness in young children</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2021</year><volume>203</volume><fpage>594</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1164/rccm.202005-1660OC</pub-id><pub-id pub-id-type="pmid">32871092</pub-id><pub-id pub-id-type="pmcid">PMC7924568</pub-id></element-citation></ref><ref id="B172-vaccines-13-00569"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Muresan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mcfarland</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Perlowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Libous</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jeanphilippe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moyejr</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/DNS2/D1313/I1314L and RSV/276 in RSV-Seronegative Children</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>226</volume><fpage>2069</fpage><lpage>2078</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac253</pub-id><pub-id pub-id-type="pmid">35732186</pub-id><pub-id pub-id-type="pmcid">PMC10205613</pub-id></element-citation></ref><ref id="B173-vaccines-13-00569"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luongo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wanionek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group><article-title>Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/&#916;NS2/&#916;1313/I1314L in RSV-Seronegative Children</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz408</pub-id><pub-id pub-id-type="pmid">31605113</pub-id><pub-id pub-id-type="pmcid">PMC7199783</pub-id></element-citation></ref><ref id="B174-vaccines-13-00569"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alamares-Sapuay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kishko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parrington</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delagrave</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Castens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Swerczek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luongo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Mutations in the F protein of the liveattenuated respiratory syncytial virus vaccine candidate &#916;NS2/&#916;1313/I1314L increase the stability of infectivity and content of prefusion F protein</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><elocation-id>e0301773</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0301773</pub-id><pub-id pub-id-type="pmid">38593167</pub-id><pub-id pub-id-type="pmcid">PMC11003679</pub-id></element-citation></ref><ref id="B175-vaccines-13-00569"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert-Guroff</surname><given-names>M.</given-names></name></person-group><article-title>Replicating and non-replicating viral vectors for vaccine development</article-title><source>Curr. Opin. Biotechnol.</source><year>2007</year><volume>18</volume><fpage>546</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.010</pub-id><pub-id pub-id-type="pmid">18063357</pub-id><pub-id pub-id-type="pmcid">PMC2245896</pub-id></element-citation></ref><ref id="B176-vaccines-13-00569"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meisinger-Henschel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tzatzaris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hulsemann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lukassen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wulff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hausmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Howley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>P.</given-names></name></person-group><article-title>Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>7442</fpage><lpage>7450</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.095</pub-id><pub-id pub-id-type="pmid">19539582</pub-id></element-citation></ref><ref id="B177-vaccines-13-00569"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sancho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schleich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krijnse-Locker</surname><given-names>J.</given-names></name></person-group><article-title>The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>8318</fpage><lpage>8334</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.16.8318-8334.2002</pub-id><pub-id pub-id-type="pmid">12134037</pub-id><pub-id pub-id-type="pmcid">PMC155139</pub-id></element-citation></ref><ref id="B178-vaccines-13-00569"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group><article-title>Nonreplicating vaccinia vector efficiently expresses recombinant genes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>10847</fpage><lpage>10851</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.22.10847</pub-id><pub-id pub-id-type="pmid">1438287</pub-id><pub-id pub-id-type="pmcid">PMC50439</pub-id></element-citation></ref><ref id="B179-vaccines-13-00569"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reichhardt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silbernagl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vidojkovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weidenthaler</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>2608</fpage><lpage>2619</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.01.055</pub-id><pub-id pub-id-type="pmid">32057576</pub-id></element-citation></ref><ref id="B180-vaccines-13-00569"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.</given-names></name></person-group><article-title>Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial with a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine</article-title><source>J. Infect. Dis.</source><year>2021</year><volume>223</volume><fpage>1062</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa460</pub-id><pub-id pub-id-type="pmid">32726422</pub-id></element-citation></ref><ref id="B181-vaccines-13-00569"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>V.</given-names></name><name name-style="western"><surname>Silbernagl</surname><given-names>G.</given-names></name></person-group><article-title>A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>126427</fpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.126427</pub-id><pub-id pub-id-type="pmid">39461302</pub-id></element-citation></ref><ref id="B182-vaccines-13-00569"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krarup</surname><given-names>A.</given-names></name><name name-style="western"><surname>Truan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Furmanova-Hollenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogaert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bouchier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bisschop</surname><given-names>I.J.M.</given-names></name><name name-style="western"><surname>Widjojoatmodjo</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8143</fpage><pub-id pub-id-type="doi">10.1038/ncomms9143</pub-id><pub-id pub-id-type="pmid">26333350</pub-id><pub-id pub-id-type="pmcid">PMC4569726</pub-id></element-citation></ref><ref id="B183-vaccines-13-00569"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Omoruyi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paepe</surname><given-names>E.d.</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Zeeburg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Godeaux</surname><given-names>O.</given-names></name><name name-style="western"><surname>Langedijk</surname><given-names>J.P.M.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged &#8805;60 Years</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>979</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa193</pub-id><pub-id pub-id-type="pmid">32320465</pub-id></element-citation></ref><ref id="B184-vaccines-13-00569"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stuart</surname><given-names>A.S.V.</given-names></name><name name-style="western"><surname>Virta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seppa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hartvickson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Greenland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Omoruyi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Haazen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Salisch</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18&#8211;50 Years and RSV-Seropositive Children 12&#8211;24 Months</article-title><source>J. Infect. Dis.</source><year>2023</year><volume>227</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac407</pub-id><pub-id pub-id-type="pmcid">PMC9796164</pub-id><pub-id pub-id-type="pmid">36259542</pub-id></element-citation></ref><ref id="B185-vaccines-13-00569"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paepe</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Haazen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Omoruyi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Comeaux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heijnen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strout</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Callendret</surname><given-names>B.</given-names></name></person-group><article-title>Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered with an Influenza Vaccine in Older Adults</article-title><source>J. Infect. Dis.</source><year>2021</year><volume>223</volume><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa409</pub-id><pub-id pub-id-type="pmid">32851411</pub-id></element-citation></ref><ref id="B186-vaccines-13-00569"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paepe</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>DeVincenzo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gymnopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Menten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haazen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Noulin</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV. preF in a Human Challenge Study</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>226</volume><fpage>396</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab003</pub-id><pub-id pub-id-type="pmid">33400792</pub-id><pub-id pub-id-type="pmcid">PMC9417128</pub-id></element-citation></ref><ref id="B187-vaccines-13-00569"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gymnopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ervin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Menten</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Paepe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.K.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of an Ad26.RSV.preF&#8211;RSV preF Protein Vaccine in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2207566</pub-id><pub-id pub-id-type="pmid">36791161</pub-id></element-citation></ref><ref id="B188-vaccines-13-00569"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Hosman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.K.H.</given-names></name><name name-style="western"><surname>Douoguih</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heijnen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Comeaux</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Callendret</surname><given-names>B.</given-names></name><name name-style="western"><surname>Allaw</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term efficacy and immunogenicity of Ad26.RSV.preF&#8211;RSV preF protein vaccine (CYPRESS): A randomised, double-blind, placebo-controlled, phase 2b study</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>1015</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00226-3</pub-id><pub-id pub-id-type="pmid">38801826</pub-id></element-citation></ref><ref id="B189-vaccines-13-00569"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spearman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knopp</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gingerich</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tellier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Radziewicz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Intranasal parainfluenza virus type 5 (PIV5)&#8211;vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study</article-title><source>Sci. Adv.</source><year>2023</year><volume>9</volume><fpage>eadj7611</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adj7611</pub-id><pub-id pub-id-type="pmid">37878713</pub-id><pub-id pub-id-type="pmcid">PMC10599610</pub-id></element-citation></ref><ref id="B190-vaccines-13-00569"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.</given-names></name></person-group><article-title>mRNA vaccines for infectious diseases: Principles, delivery and clinical translation</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>817</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmid">34433919</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id></element-citation></ref><ref id="B191-vaccines-13-00569"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parhiz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Atochina-Vasserman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA-based therapeutics: Looking beyond COVID-19 vaccines</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>1192</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02444-3</pub-id><pub-id pub-id-type="pmid">38461842</pub-id></element-citation></ref><ref id="B192-vaccines-13-00569"><label>192.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Moderna</collab></person-group><article-title>Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://s29.q4cdn.com/435878511/files/doc_news/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR-2024.pdf" ext-link-type="uri">https://s29.q4cdn.com/435878511/files/doc_news/Moderna-Receives-U.S.-FDA-Approval-for-RSV-Vaccine-mRESVIAR-2024.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B193-vaccines-13-00569"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Mithani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L.</given-names></name><name name-style="western"><surname>El Asmar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schnyder-Ghamloush</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaefers</surname><given-names>K.</given-names></name><name name-style="western"><surname>August</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stoszek</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>230</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiae035</pub-id><pub-id pub-id-type="pmid">38298125</pub-id><pub-id pub-id-type="pmcid">PMC11420805</pub-id></element-citation></ref><ref id="B194-vaccines-13-00569"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mithani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Panozzo</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>230</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiae081</pub-id><pub-id pub-id-type="pmid">38385566</pub-id><pub-id pub-id-type="pmcid">PMC11420773</pub-id></element-citation></ref><ref id="B195-vaccines-13-00569"><label>195.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA/VRBPAC</collab></person-group><article-title>Considerations for Respiratory Syncytial Virus (RSV) Vaccine Safety in Pediatric Populations</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/184301/download" ext-link-type="uri">https://www.fda.gov/media/184301/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B196-vaccines-13-00569"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wanionek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group><article-title>Evaluation of a live attenuated human metapneumovirus vaccine in adults and children</article-title><source>J. Pediatric Infect. Dis. Soc.</source><year>2018</year><volume>7</volume><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1093/jpids/pix006</pub-id><pub-id pub-id-type="pmid">28444226</pub-id><pub-id pub-id-type="pmcid">PMC6075531</pub-id></element-citation></ref><ref id="B197-vaccines-13-00569"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>August</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Knightly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kalidindia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Seger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults</article-title><source>Open Forum Infect. Dis.</source><year>2022</year><volume>9</volume><fpage>ofac206</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofac206</pub-id><pub-id pub-id-type="pmid">35794943</pub-id><pub-id pub-id-type="pmcid">PMC9251669</pub-id></element-citation></ref><ref id="B198-vaccines-13-00569"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghamloush</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kalidindi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morsy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Egwuenu-Dumbuya</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lackey</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children</article-title><source>Pediatrics</source><year>2024</year><volume>153</volume><fpage>e2023064748</fpage><pub-id pub-id-type="doi">10.1542/peds.2023-064748</pub-id><pub-id pub-id-type="pmid">38738290</pub-id></element-citation></ref><ref id="B199-vaccines-13-00569"><label>199.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>AstraZeneca</collab></person-group><article-title>Acquisition of Icosavax Completed</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html" ext-link-type="uri">https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B200-vaccines-13-00569"><label>200.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Vicebio Australia Proprietary Limited</collab></person-group><article-title>A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06556147?cond=VXB-241&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06556147?cond=VXB-241&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B201-vaccines-13-00569"><label>201.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>NIAID</collab></person-group><article-title>Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to &lt;60 Months of Age</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06546423?cond=hmpv&amp;intr=VACCINE&amp;rank=5" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06546423?cond=hmpv&amp;intr=VACCINE&amp;rank=5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B202-vaccines-13-00569"><label>202.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Sanofi Pasteur</collab></person-group><article-title>Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06134648?cond=NCT06134648&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06134648?cond=NCT06134648&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B203-vaccines-13-00569"><label>203.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Sanofi Pasteur</collab></person-group><article-title>Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06583031?cond=NCT06583031&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06583031?cond=NCT06583031&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B204-vaccines-13-00569"><label>204.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Sanofi Pasteur</collab></person-group><article-title>Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06237296?cond=NCT06237296&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06237296?cond=NCT06237296&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B205-vaccines-13-00569"><label>205.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Sanofi Pasteur</collab></person-group><article-title>Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06604767?cond=NCT06604767&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06604767?cond=NCT06604767&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B206-vaccines-13-00569"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wijesundara</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Avumegah</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lackenby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>K.J.</given-names></name></person-group><article-title>Rapid Response Subunit Vaccine Design in the Absence of Structural Information</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>592370</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.592370</pub-id><pub-id pub-id-type="pmid">33250897</pub-id><pub-id pub-id-type="pmcid">PMC7672035</pub-id></element-citation></ref><ref id="B207-vaccines-13-00569"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chappell</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Mordant</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Ellenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lackenby</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>S.T.M.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Avumegah</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: A randomised, double-blind, placebo-controlled, phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>1383</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00200-0</pub-id><pub-id pub-id-type="pmid">33887208</pub-id><pub-id pub-id-type="pmcid">PMC8055208</pub-id></element-citation></ref><ref id="B208-vaccines-13-00569"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMillan</surname><given-names>C.L.D.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>S.T.M.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Amarilla</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.Y.Y.</given-names></name><name name-style="western"><surname>Guilfoyle</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Amerongen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stittelaar</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses</article-title><source>npj Vaccines</source><year>2021</year><volume>6</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00395-4</pub-id><pub-id pub-id-type="pmid">34750396</pub-id><pub-id pub-id-type="pmcid">PMC8575991</pub-id></element-citation></ref><ref id="B209-vaccines-13-00569"><label>209.</label><element-citation publication-type="webpage"><article-title>Vicebio Pipeline targeting Respiratory Viruses</article-title><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vicebio.com/pipeline/" ext-link-type="uri">https://vicebio.com/pipeline/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref><ref id="B210-vaccines-13-00569"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pizzorno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavanagh</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Padey</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Uyar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Venable</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Carbonneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Traversier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Julien</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Strain-dependent impact of G and SH deletions provide new insights for live-attenuated HMPV vaccine development</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>164</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7040164</pub-id><pub-id pub-id-type="pmid">31671656</pub-id><pub-id pub-id-type="pmcid">PMC6963613</pub-id></element-citation></ref><ref id="B211-vaccines-13-00569"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogonczyk-Makowska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vacher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chupin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Droillard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carbonneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>E.</given-names></name><name name-style="western"><surname>Duli&#232;re</surname><given-names>V.</given-names></name><name name-style="western"><surname>Traversier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Terrier</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice</article-title><source>npj Vaccines</source><year>2024</year><volume>9</volume><fpage>111</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00899-9</pub-id><pub-id pub-id-type="pmid">38898106</pub-id><pub-id pub-id-type="pmcid">PMC11187144</pub-id></element-citation></ref><ref id="B212-vaccines-13-00569"><label>212.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Vaxxel</collab></person-group><article-title>Preclinical In Vivo Efficacy Results on Vaxxel &#8217;s Intranasal Vaccine Candidate Against Pneumovirus Infections Confirmed Through Study Funded by National Institute of Allergy and Infectious Diseases (Part of the U.S. National Institutes of Health)</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://lyonbiopole.com/wp-content/uploads/2024/10/Vaxxell-PR-NIAID-20241001-EN-VDEF1.pdf" ext-link-type="uri">https://lyonbiopole.com/wp-content/uploads/2024/10/Vaxxell-PR-NIAID-20241001-EN-VDEF1.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-27">(accessed on 27 February 2025)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00569-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic representation of prefusion (<bold>A</bold>) RSV-F (PDB ID: 8W3P) or (<bold>B</bold>) postfusion RSV-F (PDB ID: 3RRT); schematic representation of (<bold>C</bold>) prefusion HMPV-F PDB ID: 7SEJ) or (<bold>D</bold>) postfusion HMPV-F (PDB ID: 7m0i); genome organization of (<bold>E</bold>) HMPV or (<bold>F</bold>) RSV. Created with PyMOL and BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00569-g001.jpg"/></fig><fig position="float" id="vaccines-13-00569-f002" orientation="portrait"><label>Figure 2</label><caption><p>Pneumoviruses preventive modalities timeline.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00569-g002.jpg"/></fig><table-wrap position="float" id="vaccines-13-00569-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00569-t001_Table 1</object-id><label>Table 1</label><caption><p>Phase 3 clinical trials of approved RSV vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine/Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Participants</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunization Scheme</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>
<italic toggle="yes">AREXVY</italic>
<sup>&#174;</sup>
</bold>
<break/>
<bold>GSK</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of efficacy <break/>against RSV-LRTD <break/>in older adults <break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04886596">NCT04886596</ext-link> </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults <break/>(&#8805;60 yrs.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- RSVPreF3 Group: Administration of a <break/>Single dose of <break/>RSVPreF3 OA or placebo <break/>before RSV season</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Efficacy of 1 dose against RSV-LRTD:</p></list-item><list-item><label>-</label><p>82.6% (96.95% CI, 57.9 to 94.1);</p></list-item><list-item><label>-</label><p>Efficacy of 1 dose against Severe RSV-LRTD:</p></list-item><list-item><label>-</label><p>94.1% (95% CI, 62.4 to 99.9);</p></list-item><list-item><label>-</label><p>Efficacy of 1 dose against RSV-ARI:</p></list-item><list-item><label>-</label><p>71.7% (95% CI, 56.2 to 82.3);</p></list-item><list-item><label>-</label><p>Median follow-up of 6.7 months</p></list-item><list-item><label>-</label><p>Efficacy consistent regardless of subtypes and condition.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-vaccines-13-00569" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of efficacy <break/>and Safety in older <break/>adults over 2 RSV <break/>seasons &#8211;<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04886596">NCT04886596</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults<break/>(&#8805;60 yrs.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">- Extension of above <break/>study for year 2<break/>- Second vaccine dose <break/>after 1 year (revaccination) or not</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Efficacy of 1 dose against RSV-LRTD over 2 seasons:</p></list-item><list-item><label>-</label><p>67.2% (97.5% CI: 48.2&#8211;80.0%);</p></list-item><list-item><label>-</label><p>Efficacy of 1 dose against Severe RSV-LRTD over 2 seasons: 78.8% (95% CI: 52.6&#8211;92.0%);</p></list-item><list-item><label>-</label><p>Revaccination efficacy against RSV-LRTD:</p></list-item><list-item><label>-</label><p>67.1% (97.5% CI: 48.1&#8211;80.0%);</p></list-item><list-item><label>-</label><p>Revaccination efficacy against Severe RSV-LRTD:</p></list-item><list-item><label>-</label><p>78.8% (95% CI: 52.5&#8211;92.0%);</p></list-item><list-item><label>-</label><p>Median follow-up 17.8 months</p></list-item><list-item><label>-</label><p>Revaccination did not improve efficacy.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-vaccines-13-00569" ref-type="bibr">116</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>
<italic toggle="yes">ABRYSVO</italic>
</bold>
<bold>
<sup>&#174;</sup>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV Vaccine Efficacy <break/>Study in Older Adults Immunized against <break/>RSV Disease (RENOIR)&#8211;<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05035212">NCT05035212</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults <break/>(&#8805;60 yrs.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of single <break/>dose (120 &#956;g) of RSVpreF<break/>or placebo </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>No evident safety concern reported;</p></list-item><list-item><label>-</label><p>Efficacy against RSV-LRTI with at least two signs or symptoms: 66.7% (96.66% CI, 28.8 to 85.8);</p></list-item><list-item><label>-</label><p>Efficacy against RSV-LRTI with at least three signs or symptoms: 85.7% (96.66% CI, 32.0 to 98.7);</p></list-item><list-item><label>-</label><p>Efficacy against RSV-ARI with at least two signs or symptoms: 62.1% (95% CI, 37.1 to 77.9).</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-vaccines-13-00569" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maternal Immunization <break/>Study for Safety and<break/>Efficacy (MATISSE)&#8211;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04424316">NCT04424316</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnant women <break/>at 24 through 36 weeks&#8217; gestation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of single <break/>dose (120 &#956;g) of RSVpreF <break/>or placebo</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Efficacy against medically attended severe RSV-LRTI within 90 days after birth: 81.8% (99.5% CI, 40.6 to 96.3);</p></list-item><list-item><label>-</label><p>Efficacy against medically attended severe RSV-LRTI within 180 days after birth: 69.4% (97.58% CI, 44.3 to 84.1);</p></list-item><list-item><label>-</label><p>Efficacy against medically attended RSV-LRTI within 90 days after birth: 57.1% (99.5% CI, 14.7 to 79.8).</p></list-item><list-item><label>-</label><p>Effective against medically attended severe RSV-associated lower respiratory tract illness in infants, but criterion not met for medically attended RSV-associated lower respiratory tract illness (the statistical success criterion for this end point&#8212;lower boundary of the confidence interval &gt; 20%&#8212;was not met).</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-vaccines-13-00569" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic toggle="yes">mRESVIA</italic><sup>&#174;</sup></bold>&#160;<break/><bold>Moderna</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of safety <break/>and efficacy of <break/>mRNA-1345 in preventing <break/>a first episode of <break/>RSV-LRTD in older adults (ConquerRSV)<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05127434">NCT05127434</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults <break/>(&#8805;60 yrs.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of one dose<break/>of mRNA-1345 (50 &#956;g) or placebo</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>No evident safety concern reported in a median follow-up of 112 days;</p></list-item><list-item><label>-</label><p>Efficacy against RSV-LRTD with at least two signs or symptoms: 83.7% (95.88% CI, 66.0 to 92.2);</p></list-item><list-item><label>-</label><p>Efficacy against RSV-LRTD with at least three signs or symptoms: 82.4% (96.36% CI, 34.8 to 95.3);</p></list-item><list-item><label>-</label><p>Efficacy against RSV-ARD: 68.4% (95% CI, 50.9 to 79.7);</p></list-item><list-item><label>-</label><p>Protection consistent regardless of RSV subtypes, age, and conditions.</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-vaccines-13-00569" ref-type="bibr">119</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LRTI = lower respiratory tract infection; LRTD = lower respiratory tract disease; CI = confidence interval; ARI = acute respiratory infection; ARD = acute respiratory disease.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00569-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00569-t002_Table 2</object-id><label>Table 2</label><caption><p>Combination vaccines, including HMPV, have entered clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine/Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Population Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">
<bold>- mRNA-1653/</bold>
<break/>
<bold>Moderna</bold>
</td><td rowspan="2" align="center" valign="middle" colspan="1">Two mRNAs<break/>encoding full-length <break/>of HMPV-F and <break/>PIV3-F<break/>co-formulated <break/>in LNP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy adults <break/>aged 18&#8211;49 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose selection <break/>phase, evaluation <break/>of safety and immunogenicity&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03392389">NCT03392389</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Well tolerated</p></list-item><list-item><label>-</label><p>Maximum increase in nAbs titers reached with one dose</p></list-item><list-item><label>-</label><p>HMPV nAbs remained above baseline through month 13, whereas PIV3 nAbs titers declined at month 13 to baseline</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B197-vaccines-13-00569" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
Children aged 18<break/>
to 55 months
</td><td align="center" valign="middle" rowspan="1" colspan="1">Phase 1b, <break/>evaluation in seropositive children&#8212;<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04144348">NCT04144348</ext-link></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Increase in nAbs titers GMF: HMPV/A = 2.9&#8211;6.1, HMPV/B = 6.2&#8211;13.2, PIV3 = 2.8&#8211;3.0</p></list-item><list-item><label>-</label><p>Increase in bAbs titers GMF: HMPV preF = 5.3&#8211;6.1, HMPV postF = 4.6&#8211;6.5, PIV3 preF = 13.9&#8211;14.2, PIV postF = 11.0&#8211;12.1</p></list-item><list-item><label>-</label><p>Binding antibody responses were generally preF biased, and no benefit of a second dose</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B198-vaccines-13-00569" ref-type="bibr">198</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>- mRNA-1365/</bold>
<break/>
<bold>Moderna</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">mRNAs encoding <break/>RSV-F stabilized in <break/>the preF conformation<break/>and HMPV-F, encapsulated in LNP</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
Children aged 5 months
<break/>
to &lt;24 Months
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of safety, tolerability, and immunogenicity&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05743881">NCT05743881</ext-link></td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Imbalance in the number of clinically significant severe/very severe LRTI reported in the vaccine group:</p></list-item><list-item><label>-</label><p>Three patients aged 8 months developed severe RSV-LRTI with one very severe case</p></list-item><list-item><label>-</label><p>Two HMPV hospitalizations reported</p></list-item></list>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B195-vaccines-13-00569" ref-type="bibr">195</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>- IVX-A12/</bold>
<break/>
<bold>Icosavax, Inc.</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bivalent <break/>combination<break/>Of RSVpreF-VLP <break/>(IVX-121) and HMPVpreF-VLP <break/>(IVX-241) </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Older adults</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Evaluation of safety and immunogenicity of three<break/>dosage levels <break/>(low, medium, high)&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05664334">NCT05664334</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2a-Evaluation of immunogenicity and safetyNCT05903183</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>Well-tolerated</p></list-item><list-item><label>-</label><p>Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and HMPV one month after vaccination and reconfirm previous immunogenicity data seen in the phase I trial.</p></list-item></list>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B199-vaccines-13-00569" ref-type="bibr">199</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2-Characterization of immunogenicity and safetyNCT06481579</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>- VXB-241/</bold>
<break/>
<bold>Vicebio Australia</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Molecular Clamp Stabilized Prefusion<break/>F Glycoprotein Subunit Bivalent <break/>RSV and HMPV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults With Run-in in Young Adults<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of <break/>safety, reactogenicity, <break/>and immunogenicity of four dose levels&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06556147">NCT06556147</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B200-vaccines-13-00569" ref-type="bibr">200</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>- B/HPIV3/HMPV-PreF-A</bold>
<break/>
<bold>- B/HPIV3/HMPV-F-B365</bold>
<break/>
<break/>
<bold>NIAID</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two recombinant LAVs B/HPIV3 <break/>vectors expressing fusion proteins of HMPV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children 24 to &lt;60 Months of Age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study of the infectivity, safety, and immunogenicity in HPIV3-Seropositive children&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06546423">NCT06546423</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B201-vaccines-13-00569" ref-type="bibr">201</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>- RSV/HMPV</bold>
<bold>Sanofi Pasteur</bold>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bivalent RSV/HMPV mRNA-LNP </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults <break/>(&#8805;60 yrs.)</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Phase 1/2a, evaluation <break/>of safety and<break/> immunogenicity&#8212;<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06134648">NCT06134648</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B202-vaccines-13-00569" ref-type="bibr">202</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults <break/>(60&#8211;75 yrs.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of <break/>safety and immunogenicity&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06583031">NCT06583031</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B203-vaccines-13-00569" ref-type="bibr">203</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Participants aged 18 to 49 years and <break/>60 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of <break/>safety and immunogenicity&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06237296">NCT06237296</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B204-vaccines-13-00569" ref-type="bibr">204</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>- RSV/HMPV/PIV3</bold>
<bold>Sanofi Pasteur</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined RSV, <break/>HMPV, PIV3<break/>mRNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Older adults <break/>(&#8805;60 yrs.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation of <break/>safety and immunogenicity&#8212;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06604767">NCT06604767</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B205-vaccines-13-00569" ref-type="bibr">205</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: nAbs = neutralizing antibodies; bAbs = binding antibodies; GMF = geometric mean fold; preF = prefusion; postF = postfusion; LRTI = lower respiratory tract infection; LNP = lipid nanoparticle.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>